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POPULAR ABSTRACT
The skeleton is a dynamic organ that is constantly renewing itself to maintain its 
strength. Starting at birth and during childhood, bone grows and changes shape in 
order to adjust to physical requirements. As we get older, bone is lost, and this loss 
might lead to conditions such as osteoporosis. Bone growth/adjustment requires 
continually replacement of old bone by new one. This process is called bone 
remodeling, which is composed of bone resorption followed by bone formation. 
The bone resorbing cell, the osteoclast (OC), is one of the three main cells types in 
bone; the other are osteoblasts (OB), which form bone, and the osteocytes (OYs) 
which play a key role in translating mechanical signals into biological responses. 
When imbalances in the remodeling cycle occur, such as if the OCs work harder 
than they should, the result is bone loss, accompanied by a higher chance of frac-
tures. Examples of excessive resorption are found in diseases like osteoporosis, 
rheumatoid arthritis, glucocorticoids treatments and some cancers. 
Tartrate-resistant acid phosphatase (TRAP) is an enzyme existing as two  isoforms, 
TRAP 5a and TRAP 5b. OCs produce vast amounts of TRAP isoforms,  however, 
little is known about the role of these isoforms in bone remodeling. Therefore, the 
aim of this thesis was to investigate the role of TRAP isoforms in bone remodeling. 
For this, we developed an ELISA that allowed us to measure the concertation of 
both TRAP isoforms in different samples. We found that OCs can secrete both 
isoforms and that they correlate to resorption markers. This is a new discovery, 
as it has never been reported before that OCs secrete TRAP 5a, which is a marker 
for chronic inflammation. We also studied the expression of TRAP isoforms in 
synovial fluid from rheumatic diseases. TRAP can activate other proteins by 
removing phosphate groups. Osteopontin plays a role in inflammatory diseases and 
TRAP is able to modify its configuration to make it more active. We showed that 
decreased  levels of TRAP 5b could induce inflammation in rheumatoid arthritis. 
We theorized that the lower formation of OCs in an inflammatory environ ment, 
decreases the OC-mediated conversion of TRAP 5a to TRAP, leading to an inflam-
matory response and finally to the disease. We finally studied the biological role 
of TRAP by using an inhibitor of the enzymatic activity of TRAP 5b, and found 
that OC formation was mostly impaired and the expression of OC markers was 
downregulated. However, the OC that survived, were still active and able to resorb. 
Overall, TRAP seems to play an important role in bone diseases, and TRAP mal-
function seems to be a direct cause of bone abnormalities. We do not know yet 
which mechanisms TRAP controls inside the OC, but our results suggest that OC 
differentiation is affected by TRAP inhibition and that less cells were able to fuse 
in presence of the inhibitor. This potentially opens the door for new treatments 
to treat bone loss.
ABSTRACT
Tartrate-resistant acid phosphatase is a metalloenzyme that exists as two isoforms: 
the monomeric TRAP 5a and the proteolytically cleaved TRAP 5b, responsible for 
phosphatase activity, which is highly expressed in osteoclasts (OCs). TRAP 5b has 
been used as a serum marker of bone resorption, as it correlates with the absolute 
number of OCs and with resorption markers such as CTX-I. Despite being used as 
biomarker for bone metabolic diseases, little is known about the role of TRAP isoforms 
in OCs and thus bone remodeling (the process of bone degradation by osteoclasts, 
and bone formation by osteoblasts). Therefore, this thesis aimed to investigate the 
role of TRAP isoforms in bone remodeling. 
To enable the investigation of TRAP 5a and 5b we (1) developed a sandwich TRAP 
5a/5b ELISA for the quantification of human TRAP isoforms. This ELISA was then 
used for (2) evaluating the expression and secretion pattern of TRAP 5a and 5b in 
healthy individuals and during OC differentiation. Additionally, we used the ELISA 
to (3) investigated if TRAP protein levels correlate to osteoarthritis (OA) or rheu-
matoid arthritis (RA). Here we correlated the phosphorylation status of the known 
TRAP in vivo substrate, osteopontin, to the TRAP isoforms. (4) Using a competitive 
inhibitor for TRAP 5b, we studied the role of TRAP in OCs differentiation. Lastly, 
we (5) developed a high throughput system to identify a subclone in a murine cell 
line that is a more homogeneous and stable OC precursors that could be used as a 
screening tool for OC biology studies.
A double TRAP 5a/5b sandwich ELISA was developed and designed as a two-step 
process. Using the ELISA, we showed that in vitro cultures of OCs secrete not only 
TRAP 5b but also TRAP 5a and that both isoforms were present intracellular estab-
lishing that 5b can also be formed intracellular in OCs. Correlation between TRAP 
5a and 5b indicated a dependence between TRAP 5a and formation of 5b. There was 
a positive correlation in both serum from healthy men, and media from in vitro OC 
cultures of not only 5b but also TRAP 5a with CTX-I further suggesting that TRAP 
5a also originates partly from OCs. Measurement of TRAP 5a and 5b in synovial 
fluid from OA and RA patients revealed a correlation between low TRAP 5b/ TRAP 
5a ratio and phosphorylated osteopontin. This suggested that synovial fluid from 
RA patients contained an insufficient amount of TRAP 5b increasing levels of phos-
phorylated OPN leading to a higher OC activation and bone destruction. Inhibition 
of TRAP 5b using the competitive inhibitor, 5-phenylnicotinic acid, decreased the 
number of OCs formed and the expression of several OC markers. However, some 
OCs were able to fuse and resorb bone. 
In this thesis we show that measurement of TRAP isoforms protein is an important tool 
in research and possibly also in diagnostic to understand the biological implications of 
TRAP 5a and 5b in OCs, which may lead to therapeutic targeting of certain isoforms 
for inflammatory and metabolic bone diseases. We further show that TRAP is involved 
in the bone remodeling process in OCs and defects in TRAP may cause alterations in 
OCs function and differentiation.
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ABBREVIATIONS
5PNA 5-phenylnicotinic acid
AP-1 Activator protein-1
ALP Alcaline phosphatase
BMU Basic multicellular unit
BMD Bone mass density
BSP Bone sialoprotein
CtsK CathepsinK
CTX-I C-terminal telopeptide of type I collagen
ECM Extracellular matrix
Fe2+ Ferrous
Fe3+ Ferric
FBGC Foreign body giant cell
FSD Fuctional secretory domain
hPBMCs Human peripheral blood monocytes
IIAA Immuno-immobilization activity assay
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M-CSF macrophage
MMP-9 Metalloproteinase-9
MITF Micropthalmia transcription factor
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NFATc1 nuclear factor of activated T-cells cytoplasmic 1
OA Osteoarthritis
OB Osteoblast
OC Osteoclast
OY Osteocyte
OPN Osteopontin
OPG Osteoprotegerin
PTH Parathyroid hormone
RANKL receptor activator of NF-kB ligand
RANK receptor activator of NF-kB
RA Rheumatoid arthritis
RGD Arg-Gly-Asp peptide
RF Ruffled border
ROS Reactive oxygen species
Runx2 Runt-related transcription factor 2
SIBLING Small integrin-binding ligand, N-linked glycoprotein
SZ Sealing Zone
SPENCD Spondyloenchondrodysplasia
SLE Systemic lupus erythematosus
TRAP Tartrate-resistant acid phosphatase 5
TGF-β Transforming growth factor beta
TNF-α Tumor necrosis factor alpha
TRIP-1 TGFβR-interacting protein -1
11 INTRODUCTION
Bone is a complex, vascularized and highly dynamic tissue that together with 
 cartilage forms the skeletal system. It has to be strong and stiff to provide attach-
ment points to muscles when they propel and support the whole body. However, 
it also needs to be flexible enough to absorb the loading energy from mechanical 
forces1–4. 
The skeletal system not only provides support and protection. The skeletal system 
not only provides support and protection of our internal organs, but it is in the red 
bone marrow within the bones of the skeleton,  that red blood cells are formed. 
Bone is also considered as a metabolic organ because it serves as a calcium and 
phosphorus reserve to maintain normal physiological levels of both ions5. 
In general, bone modeling is the mechanism that alters and gives the shape of 
bones throughout life, whereas bone remodeling is the constant turnover that 
maintains and repair the bone. Bone turnover is high during the first year of life 
and later, approximately 10% of the bone is renewed every year with a complete 
renewal every 10 years6. 
1.1 Anatomy of bone
Bone tissue consists of organic and inorganic matrix components as well as four 
main bone cell types; bone-resorbing cells (osteoclasts; OCs), bone-forming cells 
(osteoblast: OBs) and two osteoblast-derived cells, called osteocytes (OYs) and 
bone lining cells. Additionally, bone has substantial extracellular matrix (ECM) 
consisting of mineral and protein components.
Morphologically, bone contain two different kinds of osseous tissue containing the 
same cells and matrix composition that can be distinguished based on  porosity: 
Cortical bone is highly compact in structure while trabecular bone is porous. 
Cortical bone forms the condensed and hard exterior, and represents 80% of the 
total bone mass. It is full of microscopic tubes that contain the bone’s blood  vessels 
and nerves, called Haversian canals. Trabecular bone represents 20% of the total 
bone mass, contained in the internal spaces. It represents 90% of the bone area 
which is in contact with the bone marrow and vessels, this make trabecular bone 
more susceptible to bone remodeling7 (Figure 1).
2Skeletal development
During embryonic development in higher vertebrates (birds and mammals), the 
first sign of bone development is the formation of mesenchymal condensations, in 
which  mesenchymal progenitors aggregate at the future skeleton location. Skeletal 
formation occurs by two different means of developmental processes, either intra­
membranous or endochondral ossification. On intramembranous ossification, the 
formation of new bone involves the direct differentiation of mesenchymal cells into 
OB to form membranous bone. During endochondral ossification the migration 
and condensations of the mesenchymal cells gives rise to chondrocytes to form 
a cartilage model that will serve as a template to be replaced with mineralized 
bone through remodeling. While long bones i.e. tibia, femur are formed by this two 
processes, flat bones such as calvaria or scapula are formed by intramembranous 
ossification8–10. 
1.2 Bone cells
Osteoclasts – bone resorbing cells
OCs are an unique type of exocrine cell that dissolve the inorganic hydroxyapatite 
mineral matrix and enzymatically degrades the organic matrix i.e. collagen type 1 
(CTX-I)11. OC are multinucleated cells derived from the hematopoietic myeloid 
lineage that arise from fusion of monocytes12. These mononuclear precursors 
can either migrate directly from the bone marrow to the bone surface or be first 
Figure 1. Anatomy of long bone. Structural organization of the proximal end of a femoral long 
bone. Enlarged diagram of compact bone from a transverse section of a long bone’s cortex, 
where the osteon is shown with all the layers, and the canaliculi formed by the osteocytes. In 
the center is the Haversian canal where the blood vessels is located. Adapted with permission 
of from Encyclopædia Britannica, Britannica ImageQuest: structure of long bone, and compact 
bone, artwork; 25 May 2016. http://quest.eb.com. Accessed 28 Oct 2019.
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3attracted to the peri pheral blood circulation and then recruited to the bone surface 
by different factors e.g. sphingosine-1 phosphate13, where they mature into bone 
resorbing OCs14,15. Their differentiation is principally regulated by the regulator 
system consisting of macrophage colony stimulating factor (M-CSF, encoded by 
CFS1), receptor activator of NF-kB ligand (RANKL; encoded by Tnfsf11), its 
membrane receptor activator of NF-kB (RANK; encoded by Tnfrsf11a) and the 
soluble factor osteoprotegerin (OPG; encoded by Tnfrsf11b)16. 
Osteoblast – bone formation cells
On the other hand, OBs originate from the mesenchymal lineage and their dif-
ferentiation is regulated by a plethora of hormones and cytokines e.g.  parathyroid 
hormone (PTH), estrogen, glucocorticoids and vitamin D17. The stem cell commit-
ment towards the OB lineage involves the expression of specific genes,  including 
the master gene of osteoblastic regulation: Runt-related transcription factor 2 
(Runx2)18. 
Mature OBs produce an unmineralized organic bone matrix (osteoid) composed 
of collagen type 1, osteopontin (OPN) and sialoproteins which aid to its miner-
alization11. OB functions include (1) regulation of bone-resorbing activity by a 
wide range of compounds e.g. prostaglandin E2, interleukin-1(IL-1), IL-6 and 
RANKL16,19,20 and (2) osteoclastogenesis through the RANKL/RANK/OPG path-
way21–23 among others pathways e.g. Notch signaling24,25. 
Bone lining cells/stromal cells
Bone lining cells are inactive OB,  characterized by its  flattened cell  morphology 
with fewer organelles, and cover the bone surfaces not going through bone forma-
tion or remodeling. They reside in the outer part of the trabecular bone (endos-
teum) and the outer part of the cortical bone (periosteum), like a protective layer, 
thus preventing the homing of other cells to the bone surface. These lining cells 
are thought to have a role in the recruitment of OC26 and in coupling OC and OB 
activity during the bone remodeling cycle by removing the protruding collagen 
from the bone surface and allowing the OB to form new bone27. 
Osteocytes – bone mechanoreceptors 
Most past studies agree that OYs are terminally differentiated OBs that were 
trapped within the resorption lacuna after matrix deposition but recently this is 
debated as it has been shown that OYs have the ability to regain an OB pheno-
type6. OY have been described as the neurons of the skeleton because of their 
characteristic shape with canaliculi (tiny channels) communicating the bone cells 
and the vascular system with the bone surface28–30. OY death by micro-damage 
has been suggested to translate the mechanical loads forces into biological signals 
that regulate bone remodeling31,32.
41.3 Extracellular bone matrix (ECM)
Bone matrix is composed of an organic based framework and an inorganic min-
eral phase. The major organic component is collagen type I fibrils (about 90% 
of the total protein mass), and it is upon these collagens fibrils that the inorganic 
hydroxyapatite (Ca10(PO4)6(OH)2) crystals are deposited and confer strength and 
stiffness to the bone. The remaining 10% of the organic phase contains a  relatively 
small amount of some minor types of collagen III and IV, fibronectin and non-
collagenous proteins, including proteoglycans, glycosylated proteins such as small 
integrin-binding ligand (SIBLING), osteocalcin, and lipids and the bone cells33. An 
important subgroup of non-collagenous proteins is the RGD-containing proteins 
such as bone sialoprotein (BSP), OPN, osteocalcin, thrombospondin and vitronectin. 
Integrins that recognize the RGD sequence mediate cell-matrix contact34,35. Most 
of non-collagenous proteins are synthesized by the OB but the liver synthesizes 
approximately a quarter of them which are absorbed directly through the ECM. 
Osteocalcin is the more abundant non-collagenous protein produced by the OB 
(approx. 1%) and may play a role regulating bone formation as it was suggested 
by the increased bone mass observed in the osteocalcin knockout mice36. 
Osteopontin
OPN is expressed not only in the bone matrix but in a variety of soft tissues e.g. 
vessels and immune cells37,38 e.g. T cells. OPN is a highly phosphorylated glyco-
protein believed to be secreted by OCs and deposited into the resorption lacunae 
during bone resorption39. OPN belongs to the SIBLING family and is character-
ized by its flexible structure that enables OPN to interact with other proteins e.g. 
collagens and hydroxyapatite crystals40. When dephosphorylated – by for e.g. 
Tartrate-resistant acid phosphatase 5b (TRAP 5b) or alkaline phosphatase (ALP), 
(see sections 3.3 and 3.2.4). OPN-facilitates OCs adhesion and initiates osteoid 
mineralization41. In its phosphorylated form it inhibits hydroxyapatite crystal for-
mation and growth42. 
The main role of OPN during inflammation is to trigger myeloid and lymphoid 
cells to secrete cytokines to drive the inflammatory/immune response38.
1.4 The bone remodeling cycle 
To maintain a healthy skeleton with optimal mechanical integrity, bone is constantly 
remodeled throughout life. The bone remodeling cycle is necessary for (1) fracture 
healing and (2) adaptation to mechanical forces by modifying the structure of bone 
and repairing micro-damage26,43. (3) It also serve to maintain calcium homeosta-
sis44. During the remodeling cycle, the integrity of the skeleton is maintained by 
the coordinated formation and resorption of bone, enabling to replace the foci and 
damaged bone by new bone, thus helping to keep bones healthy. 
5The coupled activity of OBs and OCs is mainly determine by bone remodeling. 
Coupling refers to the coordinated actions of OCs and OBs during remodelling. 
Damage or stress applied to the bone can be sensed by the OYs and activate the 
bone remodeling cycle. These actions are performed in clusters arranged within tem-
porary anatomical structures known as the ‘’Basic Multicellular Unit’’ (BMU)45,46. 
While each BMU occurs in a determined space and within a specific time it can 
occur at many times and places asynchronously through the whole skeleton. 
The way the remodeling happens depends on the type of bone that is being 
 remodeled, even though the distinction is more morphological than  physiological 
as in both cases the cellular events follow the same sequence. The remodeling 
process can be further classified in two types: The Harversian remodeling within 
the cortical bone and the endosteal remodeling along the trabecular bone surface 
(Figure 2). In cortical bone the OCs, dig a tunnel, followed by the OBs that will 
fill with osteoid. In trabecular (also called cancellous bone) the BMU is similar, 
but it moves across the trabecular surface, where the OCs dig a trench rather than 
a tunnel47,48. In trabecular bone the capillaries or  vessels are always close to the 
remodeling unit 49,45. Both osteons and the new trabecular bone are aligned towards 
the dominant load direction. 
Figure 2. Cortical and trabecular remodeling on a long bone. Remodeling requires removal 
of bone by the OC and production of bone by the OB, thus there is coupling in the activity of 
both cells. In the remodeling process OC mobilize material, which leads to the recruitment 
of OB precursors to the bone surface that has been resorbed. The OB precursors differentiate 
into mature OB, and in normal circumstances replace the old bone that has been resorbed by 
the OC. Modified from: Coupling the activities of bone formation and resorption: a multitude 
of signals within the basic multicellular unit and from Assessment of bone vascularization 
and its role in bone remodeling50,51.
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6The traditional bone remodeling dogma describes five sequential phases of bone 
remodeling that occur in an active BMU on trabecular bone: (1) initiation/activation 
of OCs formation, (2) resorption mediated by OCs, (3) reversal period, (4) matrix 
formation by OB, and (5) mineralization/termination. Communication pathways 
exist among each of the four cell types mentioned previously45.
The reversal phase of the remodeling is the least well understood. After OC have 
resorbed bone, the surface (Howship’s lacunae) remains covered with undigested 
demineralized collagen27. Coupling of bone formation and bone resorption requires 
the recruitment of osteoproteginors, these osteoprogenitors are also named “ reversal 
cells”, and probably originate from the OB lineage48. The reversal cells’ job is 
to remove the leftovers of collagen and to prepare the bone surface for the next 
phase, bone formation. The way they achieve this goal is still very controversial 
but is probably done by producing or receiving coupling signals allowing bone 
formation within the BMU27,45. 
Signaling in bone metabolism
Bone remodeling is a tightly regulated process modulated through the interaction 
and communication of OBs, OYs and OCs. Bone diseases are characterized by 
an imbalance of these processes, for example during inflammation or in several 
bone diseases e.g. osteoporosis, where bone resorption exceeds the formation or 
bone formation exceeds resorption e.g. osteomalacia, osteopetrosis. (Figure 3)
Bone metabolism is regulated by several signaling pathways and soluble factors 
secreted by different organs. Bone formation is regulated by the WNT-β-catenin 
signaling pathway52–54. This pathway enhances the differentiation of mesenchy-
mal cells into OB55. There are antagonists that prevent the differentiation of OBs, 
and prevent bone formation such as sclerostin56 and dickkopf-related protein 157. 
Excess of vitamin A can also inhibit OB differentiation58,59. 
The OPG-RANK-RANKL pathway is required to regulate bone formation and 
resorption60. RANKL is secreted by both OBs and OYs, but OYs have been identi-
fied as the main regulators of bone remodeling61. When RANKL binds to its recep-
tor, RANK on the osteoclast stimulates bone resorption. OB produce OPG which 
is a RANKL decoy receptor as it impedes RANK-RANKL interaction by binding 
RANKL. Recently, has been identified the RANKL reverse signaling. Here, OCs 
secrete vesicular RANK that can then bind on the RANKL exposed on the OBs 
surface 62. This pathway is detailed in reviewed in section 2.1.
71.5 Coupling of bone formation and resoption
Bone deposition and bone resorption are ongoing dynamic processes. Several 
coupling signal have been proposed, some produced by OCs63 including TRAP 
5a, sphingosine 1-phosphate and the cell-anchored EphB4-ephrin-B264
There are different stimuli that contribute to coupling of the different components 
of the bone at the BMU such as (1) growth factors released from the matrix e.g. 
transforming growth factor β1 (TGFβ1). Recent evidences indicate that OC ini-
tiate remodeling by mobilizing and activating TGFβ1 that is stored in the bone 
matrix in a latent form. This mobilized growth factor targets mesenchymal stem 
cells (MSC), recruiting them to the bone surface where they differentiate into 
OBs, thereby completing bone remodeling at that particular site47,65–67. (2) soluble 
and membrane products from OCs or their precursors, e.g. semaphorin4D, that 
Figure 3. Bone remodeling cycle with a network of OYs signaling to both OCs and OBs. 1) 
Initiation/activation for OCs to differentiate and resorb 2) the OYs network secrete RANKL 
after sensing changes, mechanical strain, microdamage, bone resorption done by an OC, 3) 
Bone deposition and mineralization by the OB. By kind permission of my supervisor Tuomas 
Näreoja, Karolinska Institutet.
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8inhibits bone formation during bone resorption68,69 (3) signals from OYs e.g. slcer-
ostin, inhibiting bone formation70, (4) signals from the immune system e.g. tumor 
necrosis factor-α (TNFα) secreted by T cells enhances OC formation. In humans, 
defects in bone remodeling lead to a range of metabolic and genetic syndromes 
such as osteoporosis, Paget’s disease and osteopetrosis71. 
92 OSTEOCLAST
General organization
OCs resorb bone via the specialized bone-resorbing membrane domain called, the 
ruffled border ( RB) which is formed through trafficking and fusion of acid vesicles 
from the secretory pathway containing proton pumps and osteolytic enzymes72 and 
is used as a hallmark of an active OC73. The formation of the RB is a critical event 
for OC function. RBs do not form in certain genetic cases of osteopetrosis, severely 
reducing OC resorption and resulting in an increase in bone mass74. The RB is located 
on the basolateral side of the OC facing the resorption lacuna and consists of irregular 
deep enfolding of the plasma membrane, covering the resorption area and mediating 
secretion of resorption factors and uptake of resorption products75. 
The ruffled border is surrounded by the sealing-zone (SZ) which consists of an 
actin ring delimitating the resorption lacuna and attaches the OC to the matrix via 
the avβ3-integrin expressed in the SZ by the podosomes structures76. The attach-
ment of the ring to the bone matrix is mediated by integrin receptors i.e. αvβ3, 
binding to RGD sequences in specific bone matrix proteins e.g. vitronectin and 
OPN74. The clear zone, refers to the cytoplasmic side of the SZ and is devoid of 
organelles, but rich in actin filaments77. Following the degradation of bone matrix, 
the RB uptakes the degraded products, that are then trafficked in vesicles through 
the cell via transcytosis, to the functional secretory domain (FSD) located on the 
basal membrane, to the circulation. The membrane facing the vascular capillaries is 
called the basolateral domain, and is presented with an asymmetrical distribution 
of ion transporters. A transcytosis route is stablished between the RB and the FSD 
of the basolateral membrane, that consent the released of the bone matrix degraded 
products to the blood stream (Figure 4)73. 
Polarization
OCs attach to the bone surface by binding its surface integrins to the bone proteins 
e.g. vitronectin and OPN. The attachment arrange the cytoskeletal configuration 
into a polarized, multinuclear, secretory cell with four major structures i.e. the RB, 
the SZ, basolateral domain, and FSD (Figure 4). This polarization enables the OC 
to become active and demarks the resorption lacuna which is formed by sealing off 
the area beneath the OC and forming the acidic microenvironment that is necessary 
to resorb bone73,78–80. 
Interestingly, it was shown in a rachitic fibroblast growth factor-23 transgenic mice that 
OC polarization is not required for degradation of bone matrix81. FGF23 is involved 
in phosphate homeostasis and vitamin D vitamin metabolism, and overexpression 
impairs, mineralization82. OCs could not attach properly to the bone surface and 
polarize but resorption was still on going through secretion of cathepsin K (CtsK) and 
metalloproteinase -9 (MMP9). However TRAP was not secreted.81
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Resorption
The detection of an initiating remodeling signal attracts the monocytes to the resorp-
tion site, which leads to their fusion to form an OC and attachment of the OC to the 
bone surface. This signal can take several forms e.g. direct mechanical strain on 
the bone that results in structural damage or also hormone action on bone cells 
(estrogen, PTH)45. The adhesion is mediated through αvβ3 vitronectin receptors.83
One of the features that clearly identify an active OC from any other cell type 
(macrophages, foreign body giant cells (FBGCs) is their ability to resorb bone and 
cartilage84,85. They resorb bone during bone growth and remodeling. Alterations 
on the balance of bone formation and resorption cause different bone related 
 diseases. Bone resorption can only be performed by OCs due to their capability 
to degrade the bone matrix by (a) acidifying the mineral content and subsequent 
(b) degrading of the collagen content of the bone matrix74,86.
Once OCs undergo polarization and the RB, the FSD and the SZ are formed, the 
OCs start the solubilization of minerals (mainly hydroxyapatite) by generating 
an acidic environment through pumping protons into the resorption pit. These 
protons are generated in the cytoplasm by the enzyme carbonic anhydrase II 
and the hydrogen ions are pumped via ATPase subunits, such as ATP6V0387 and 
Figure 4. Cell organization in Osteoclasts. Transmission electron micrograph showing a 
rabbit osteoclast on dentine with 4 or 5 nuclei (N), sealing zone (SZ), ruffled border (RB) and 
the functional secretory domain (FSD. It can also notice that OC has abundant organelles and 
mitochondria. By kind permission of E. McDermott and M.H. Helfrich, University of Aberdeen.
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ATP6V0d288,89, which are essential for OCs function into the resorption lacuna90. 
To maintain electroneutrality, chloride channel 7 in the RB transports Cl- into the 
resorption lacuna91. The H+-ATPase transports also enzymes such as CtsK, MMP9 
and TRAP are secreted to the resorption lacuna to degrade the bone matrix. The 
collagen degradation (mainly type 1 collagen) is due to the activity of CtsK and 
metalloproteinases (MMPs). CtsK is a cysteine  proteinase, that proteolytically 
degrades collagen into pieces at and acidic environ ment (pH ~5)75,80. Absence of 
CtsK92 results in a mild osteosclerotic phenotype, suggesting that other enzymes 
might also contribute to the organic degradation during bone resorption. MMP9 is 
a MMPs expressed in several types of cells and implicated in the turnover of bone 
and cartilage matrix during bone remodeling. When CtsK knockout mice have 
a mild sclerotic phenotype the ablation of both CtsK and MMP9 causes severe 
osteopetrosis93 (Figure 5). 
Figure 5. Resorption process. OCs resorb bone in sequence of steps: after attaching to the 
bone through the sealing zone it has to produce acid and it does that using the enzyme carbonic 
anhydrase II which catalyzes the reaction of carbon dioxide with water to generate carbonic 
acid, the carbonate component is eliminated from the cell, the protons are pumped across the 
ruffled border into the extracellular vacuole in the resorption space and chloride ions cross 
passively in order to maintain the electrochemical balance. The acid generated, dissolves the 
hydroxyapatite component of the bone. In order to break up the collagenous component of the 
bone, the OC uses CtsK which is secreted across the ruffled border. CtsK digests the collagen 
into smaller pieces, which are then endocytose into the OC and transported across the cell to 
the extracellular environment. The result of these actions is the formation of a resorption pit.
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HCO3
CL-
Carbonic anhydrase II
HCO3
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However, OC resorption does not only form resorption pits while immobilized, 
but yet another type of resorption have been proposed as it has been shown that 
OC can move across the bone surface while resorbing, forming trenches80. Since 
the SZ surrounds the resorption pit, it was shown that during trench-mood OCs 
move over the bone surface without disabling their resorption machinery. Trenches 
reflect long, fast and aggressive bone resorption in vitro80.
It has recently been reported the existence of septins in OCs are expressed during 
differentiation94. Septins are known to support the cytoskeletal stability, vesicular 
transport, endocytosis and stabilizing cellular membranes95. The stabilization of 
septin filaments inhibits bone resorption and the conditional knockout mouse sept9 
leads to higher trabecular bone and lower femoral growth in vivo94.
Vesicular transport
After synthesis in the endoplasmic reticulum (ER), the lysosomal enzymes are 
labelled with mannose-6-phospate residues, which are recognized by their receptor 
in the trans-Golgi network. They are either packaged into clathrin-coated vesicles 
and transported by transcytosis through the cell, to the FSD or kept for digestion 
via a series of processes including endocytosis, phagocytosis, and autophagy.
2.1 Osteoclastogenesis 
OCs differentiation is mainly regulated by OBs and OYs through the RANK/RANKL/
OPG axis. As mention in section 1.4., M-CSF and RANKL43,76,96–99 are two essential 
cytokines involved in OC differentiation. Different signals enhance the production of 
these two key master regulators of OC differentiation e.g. low calcium levels enhance 
the production of calcineurin by the PTH hormones and thus enhance the levels of 
RANKL and M-CSF in order to restore the calcium levels100. 
The binding of M-CSF to its receptor, c-fms, provides signals for proliferation 
and survival that induce the expression of the receptor activator of nuclear factor 
kappa β (RANK) in OC precursors through the activation of ERK and Akt101. The 
importance of M-CSF in OCs differentiation is exemplified by a mice model for 
osteopetrosis (op/op), in which mice lack OCs and circulating monocytes due to 
a mutation in the coding region of the M-CSF gene. Addition of M-CSF to these 
mice restores OCs population and rescues the phenotype 12,102,103 
RANKL is the second key factor in OCs differentiation, which is expressed by 
OBs and OYs96,97. Mice lacking either RANKL104 or RANK receptor105 suffer from 
severe osteopetrosis and defective tooth eruption due to the complete lack of OCs. 
RANKL is a member of the TNF superfamily. The signaling activation RANK/
RANKL requires the recruitment of adaptor molecules, several of them belong to 
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the TNF receptor associated factors (TRAFs), and while several of them can bind 
to RANK, TRAF6 is the one that preferentially binds to RANK in OCs precursors. 
Once TRAF6 has bound to RANK the recruitment of activated mitogen-activated 
protein kinases (MAPKs), and activator protein-1 (AP-1) and the transcription 
factor nuclear factor-κβ (NF-κβ)106 is initiated.
Figure 6. Overview of the different steps for osteoclastogenesis. Under physiological 
conditions the monocyte differention through bone resorbing osteoclasts is regulated by two 
cytokines, M-CSF and the RANKL. M-CSF is a survival factor that stimulates the ERK and 
the Akt pathway. Under the stimulation of others cytokines the differentiation can go in dif-
ferent directions, forming dendritic cells, M1 macrophages or M2 subtypes. 
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Activated NF-kB induces the activation of nuclear factor of activated T-cells 
cytoplasmic 1 (NFATc1 or NFAT2) which is a key regulator of OCs differentia-
tion107. In addition to RANKL co-stimulatory signals, Ca2+ oscillation in osteoclast 
precursors activates phosphatase calcineurin which causes dephosphorylation of 
NFATc1 and translocation of c-Fos and NFATc1 to the nucleus, thus regulating the 
expression of OC-specific downstream target genes including TRAP, OC-associated 
immunoglobulin-like receptor (OSCAR), CtsK, calcitonin receptor, MMP9 and 
β3-integrin, leading to the development of mature osteoclasts108–110. NFATc1-
knockout mice exhibits osteopetrosis due to the inhibition of OCs differentiation 
in vivo and in vitro111.
Moreover, NFATc1 cooperates with other transcription factors such as the melano-
genesis associated transcription factor (MITF) and PU.1, that regulate mononuclear 
pre-osteoclast fusion by inducing several genes involved in the fusion process, 
such as dendritic cell-specific transmembrane protein (DC-STAMP), osteoclast-
stimulatory transmembrane protein (OC-STAMP)112 and the d2 isoform of vacu-
olar (H+) ATPase (v-ATPase) Vo domain (Atp6v0d2). It was shown recently, that 
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knockout mice for DC-STAMP113 or Atp6v0d2114 develop osteopetrosis due to a 
defective fusion process during osteoclastogenesis, thus highlighting the impor-
tance of both genes in OCs fusion, to form bone-resorbing OCs.
In addition to OCs differentiation through RANK signaling, other pathways may 
also interact with NFATc1 signaling and stimulate or inhibit its translocation into 
the nucleus and subsequent induction of the target genes for cell fusion, OCs dif-
ferentiation and function such as the triggering receptor expressed in myeloid 
cells-2 (TREM-2) and OSCAR –a collagen receptor, that actives OC on bone 
(Figure 7)115–117. Cell lacking NFATc1 were not able to differentiate to OCs, but also 
NFATc1 affects processes involved in resorption and cytoskeleton re-organization. 
Figure 7. Osteoclasts signaling pathways. Schematic representation of M-CSF, RANKL and 
co-stimulatory signaling active during osteoclastogenesis. RANKL stimulates differentiation 
through the activation of different genes. Once NFATc1 is dephosphorylated and enters into 
the nucleus enables the activation of CtsK, chloride channel-7 (CLC-7), TRAP, DC-STAMP. 
Reprinted with permission of Jung Ha Kim and Nackcsung Kim. Signaling Pathways in 
Osteoclasts Differentiation101. Copyright © Chonnam Medical Journal, 2016 Jan; 52(1): 12–17
OBs also produce the endogenous RANKL inhibitor, OPG that is a soluble decoy 
RANK receptor for RANKL. Mice deficient of OPG show osteoporosis due to 
increased number of OCs118. It is worth noticing that similar effects can be obtain 
by using a synthetic antibody against RANKL, called Denosumab, which is being 
used clinically to prevent bone loss9. Thus, the ratio between RANKL to OPG is 
critical for the skeleton. When the amount of RANKL exceeds the amount of OPG, 
bone lose will be increased and conversely when OPG exceeds RANKL, bone 
lost will be prevented. Any imbalance in bone deposition and resorption results in 
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many metabolic bone diseases. Defects in the removal of mineralized bone or in 
bone resorption result in a deficient deposition of bone that lead to osteopetrosis, 
resulting in dense but brittle bones. On the other hand, if the resorption of bone 
exceeds the deposition of bone, osteopenia (low bone mass) can occur which may 
lead to osteoporosis reducing the strength of the skeleton and limiting the mineral 
available for metabolic functions.
2.2 Osteoclast heterogeneity
Although OCs have been long considered to be an homogenous population of bone 
resorbing cells, extensive research has demonstrated the existence of functional dif-
ferences between OCs34. Bone-site specific OCs are phenotypically different e.g. in 
resorption machinery9, drug intake and in response to local or systemic hormones 
e.g. PTH119. At least two explanations have been proposed to explain the presence 
of functionally heterogenetic OCs 9; (I) It has been suggested that site-specific OC 
heterogeneity could be explained by the properties of the mineralized matrices (differ-
ent microenvironment) they resorb and, (II) different monocytes subsets give rise to 
functional different OCs, for instance, under the influence of inflammatory cytokines.
OCs precursors
Three monocytes subsets can be distinguish based on the surface markers expres-
sion: the classical monocytes, with high expression of CD14++ (LPS receptor), 
the non-classical monocytes with high expression of CD16++(immunoglobulin 
Fc-domain receptor)120, and the intermediate monocytes expressing high levels of 
CD14+ and some CD16+. 
The non-classical monocytes, are predisposed to M2 activation, respond to larger 
antibody recognized targets, and are able to trigger an immune response with the 
consecutive release of cytokines recruiting more monocytes to the inflammatory 
site. These monocytes are more likely to respond to a combination of inflammatory 
and osteoclastogenic stimuli and differentiate into inflammatory OCs that are able to 
acidify external targets and promote inflammation121,122. Everts et al. suggested that 
classical monocytes are the main source of OCs, while the inter mediate and non-
classical monocytes contribute to inflammatory conditions, giving rise to FBGCs, 
immunological osteoclast-like cells related to the macrophage population123–125. 
Foreign Body Giant Cells (FBGCs)
FBGCs are a subpopulation of multinucleated giant cells126 which develop through 
fusion of macrophages. This fusion of the monocytes/macrophages into FBGC is 
exclusively related to the presence of a foreign material84,85. Inflammatory condi-
tions can cause a cross-react in signaling pathways that guide cell differentiation, 
differentiating them into either OC or FBGCs84. 
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FBGCs and OCs share common characteristics such as TRAP expression and 
multinuclearity. However, there are several characteristics that differentiate a 
functional OC from an activated FBGCs. OCs secrete primarily TRAP 5b and 
express CtsK what allows them to resorb bone. On the other hand, FBGCs do 
not secrete TRAP 5b and are incapable of forming the RB or expressing CtsK. 
This makes them, even though they are able to acidify, fail to degrade collagen 
type I, thus failing to resorb bone84. Sprangers and Harkel performed a series of 
experiments in which they exposed the classical and non-classical monocytes to 
standard physiological conditions e.g. RANKL+MCSF and/or to inflammatory 
cytokines e.g. IL-4/IL-13127. IL-4 and IL-13 have been shown to participate in 
macrophage fusion in vitro128–130 and IL-4 has also been involved in the activa-
tion of dendritic cell–specific transmembrane protein (DC-STAMP), a fusion 
related marker131 essential for OC differentiation132 and highly expressed in OCs 
and macrophages treated with IL-4133. IL-4 has also shown to promote fusion of 
monocytes in a RANKL-independent pathway134. Their results showed that the 
non-classical monocytes treated with inflammatory cytokines were larger, with 
more nuclei, and exhibited acting rings but were not able to resorb bone and were 
consequently classified as a macrophage subpopulation of FBGCs84,135. 
Bone-site specific OCs
Everts et al., (2008) studied the protein composition between flat and long bones 
and suggested that the different bone origin could explain the functional differ-
ences observed in OCs119,136. Beertsen et al., (2009) showed that MMPs participate 
in resorption of calvarial bone but not in long bone resorption while CtsK and 
CstL participate in resorption at both bone sites, even though their activity levels 
are higher in long bone located OCs than in calvarial OCs119. Saftig et al, (1998) 
reported that CtsK knock-out mice have an osteopetrotic phenotype in long bones 
while their flat bones are normal, also indicating that different bone-site specific 
OCs might be have different functions due to differences in the expression of 
CtsK during resorption, leading to resorption defects92,137. Everts et al., (2015) 
studied the relationship between bone site specific OBs, and  OC heterogeneity. 
They found that a higher number of TRAP positive OCs arise from the calvaria 
OB, while the expression of OPG was higher in the long-bone OBs138 possibly 
inhibiting differention of OCs.
2.3 Osteoclasts in inflammation
Apart from the two essential cytokines M-CSF and RANKL involved in physi-
ological OC differentiation, some cytokines released during inflammation have 
been recognized to stimulate bone resorption in numerous rheumatic diseases. The 
most common types of arthritis are rheumatoid arthritis (RA) and osteoarthritis 
(OA). Inflammation is a common trait in both diseases; however, in RA the cause 
is autoimmunity while the cause is unknown in OA.
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During synovitis cytokines released by infiltrated T cells e.g. TNFα and inter-
leukin-17 (IL17), can up-regulate RANKL expression in OB and it is also possible 
that RANKL expressed by T-cells could increase OC differentiation139 leading to 
an enhanced resorption and thus loss of bone mass. However, activated B cells are 
also part of the infiltrate, and are a major source of OPG, hence its contribution 
to RA osteoclastogenesis in unclear. When macrophages and monocytes infiltrate 
the synovia, they also secrete MMPs that can contribute to ECM degradation. 
Even though these cells can also secrete MMPs inhibitors, the balance seems to 
be favoring matrix degradation.
As mentioned above, negative regulation of OC differentiation is also controlled 
by the soluble decoy OPG, but under pathological situations cytokines e.g. IFNα, 
IL10 and IL4 have been shown to inhibit OC differentiation and activity 14.
Rheumatoid arthritis
RA is an autoimmune disease associated with chronic inflammation that results 
in local bone loss and joint deformations caused by increased OC resorption. In 
a joint affected by RA the synovium is swollen due to an infiltrate consisting of 
fibroblast-like and macrophage-like cells and several populations of T and B cells 
that secrete different pro-inflammatory cytokines able to increase bone resorption 
such as TNFα and interleukins like IL-1, IL-17 and IL-6, and thereby degrad-
ing cartilage and bone140,141. RA is an autoimmune disease and the presence of 
autoantibodies against common antigens expressed within and outside the joints 
– rheumatoid factorand anti-citrullinated peptides antibodies, is associated with 
a more severe RA phenotype.
The contribution of OCs in RA bone loss is demonstrated by the protective effects 
of bisphosphonates and the RANKL-neutralizing antibody denosumab, as well 
as elevated serum RANKL: OPG ratios correlating with radiological disease pro-
gression. Several mechanisms involved in the pathological OC activity have been 
elucidated. Antagonists against TNFα alpha, IL-6 and IL-1b have all been proved 
effective as anti-arthritis drugs particularly the TNFα inhibitors, with regard to 
reducing RA progression and bone erosion142.
Osteoarthritis
OA starts as a cartilage disease that progressively results in a degenerative bone 
disease affecting joints. Little is known about the initiating events of OA, but 
repetitive use of the affected joints, genetic/epigenetic factors and particularly 
smoking may be implicated. Inflammation also contributes to the joint degrada-
tion and many inflammatory mediators in OA are similar to those in RA, with the 
exception of autoimmunity. 
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In a study done by Lövfall et al (2018)143, OCs were set up in a culture model 
system where human OCs degrade cartilage from the knee joints of cows and 
they are subsequently treated with inhibitors for MMPs and CtsK. They  measured 
different cartilage degradation biomarkers143,144 and showed that the MMPs con-
tributed strongly to the release of cartilage degradation markers while the con-
tribution of CtsK was low. 
2.4 Resorption inhibitors
Resorption inhibitors are drugs that inhibit OCs resorption or mineralization of the 
bone. They are used to treat bone loss in different diseases such as osteoporosis 
in postmenopausal women, glucocorticoid induced osteoporosis, Paget’s disease 
of bone and and malignant hypercalcemia.
Bisphosphonates 
Bisphosphonates are the primary pharmacological drug against OC mediated 
resorption, in order to prevent bone loss. However, implications of bisphosphates 
in pathological conditions such as osteonecrosis of the jaw has questioned its 
overuse in other skeletal disorders.
Structurally, bisphosphonates are inorganic pyrophosphate (PPi) derivatives with 
two phophonate groups (PO(OH)2). It was shown in 1960s that PPi can inhibit 
 mineralization through binding to the hydroxyapatite crystals. It was hypothesized 
that PPi regulates bone mineralization145. Bisphosphonates inhibit resorption by 
inducing apoptosis in OC146
Cathepsin K inhibitors: Odanacatib
As mentioned in section 2, CtsK is involved in collagen degradation, it is stored 
in lysosomes, and can regulate itself (proptide, glycosaminoglycans, oxidants) or 
be regulated by acidic conditions147,148. Defects in CtsK lead to pycnodysostosis, 
and autosomal recessive osteochondrodysplasia characterized by short stature, 
an increased bone mineral density and fractures. Inhibition of CtsK increases the 
bone mineral density in patients. Despite multiple efforts to develop an  inhibitor 
for CtsK as an additional treatment for osteoporosis, concerns related to off-
target effects have been considered, as CtsK is also found in a variety of tissues 
other than bone149. However, a double-blind phase III study of Odanacatib was 
approved to treat osteoporosis and the results were promising, Odanacatib was 
withdrawn from the regulatory approval after its use was linked to anincreased 
risk of  cerebrovascular accidents. 150
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3 TARTRATE-RESISTANT ACID PHOSPHATASE
Tartrate-resistant acid phosphatase 5 (TRAP; TRAcP; ACP5, PAP) is a metallo-
enzyme and a member of the purple acid phosphatase family (EC 3.1.3.2) which 
was once considered purely a histochemical marker of osteoclasts (OCs) and hairy 
cell leukemia151. Besides OCs, the enzyme is also expressed in other bone cells 
such as osteoblasts and osteocytes152,153 and on the surface of the bone matrix153. 
However, its role in bone remodeling is not well elucidated. 
3.1 TRAP isoforms 5a and 5b
Acp5 gene and transcripts
The structure of TRAP gene is well conserved among species and contains five 
exons, with the initiation site located at the beginning of Exon 2154,155. There is 
one single TRAP gene (Acp5) giving rise to three transcripts in mice and seven 
in humans156. However, these transcripts give rise to the same protein but  differ in 
their promotor and regulatory sequences157. Consequently, TRAP is likely regu-
lated by different transcription factors in different cell types158. In mice, expression 
of transcript 1A is restricted to adult bone and spleen, transcript 1B is associated 
with expression in TRAP positive cells or tissues that are not from the myeloid 
lineage e.g. OBs157. Transcript 1C is the main transcript in OC and macrophages, 
and characteristic of TRAP expression in myeloid cells157. TRAP is translated as a 
single polypeptide and TRAP isoform 5a and 5b are a result of a post-translational 
modification. 
Several transcription factors have been identified as master regulators of OCs 
 develop ment implicated in TRAP expression such as the microphthalmia 
Transcription Factor (MITF)159 and PU.1158 that recognizes specifically the sequence 
of the 1C promoter. Deletions on the PU.1 gene result in osteopetrosis due to 
impaired differentiation of myeloid cells. Transcriptional factor FoxM1 activat-
ing TRAP has also been linked to cancer metastases like in hepatocellular carci-
noma160. NFATc1 has not been shown to interact directly with the Acp5 gene, but 
after NFATc1 expression increase in TRAP expression is found161.
In murine RAW264.7 cells two regions are involved in RANKL-induced TRAP 
transcription, it was shown that the nuclear proteins that bind the promoter are 
upstream stimulatory factors (USF) 1 and 2. Mutations of these USF 1 and USF2 
block RANKL-induced TRAP expression in RAW264.7 cells162.
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Protein structure
TRAP is found as two isoforms, TRAP 5a and TRAP 5b (Table I). TRAP 5a is 
translated as a single polypeptide  ̴ 35kDa and consists of 305 amino acids. TRAP 
5b consists of two subunits that form a disulfide-linked heterodimer of 16kDa and 
23kDa163. The sequence contains two potential N-glycosylation sites (Asn 97 and 
Asn 128) located in N-terminal fragment. Mutations in the these glycosylation sites 
reduced the substrate affinity for the catalytic site164. (Figure 8)
Figure 8. Recombinant human TRAP. Protein structure resolution 2.2 Å, PDB ID 1 WAR. 
Fe atoms are highlighted in the center, the repression loop is shown in orange and the two 
possible glycosylation sites are represented in green. By kind permission of Anja Reithmeier, 
Karolinska Institutet. Graphics by Biognos AB, Martin Frank, 2015.
Table I. Properties of TRAP isoforms
TRAP 5a TRAP 5b
Sialic acid Present Not present
pH optimum 4.9-5.1 5.7-5.9
Phosphatase activity Low High
Structure Intact ~35 KDa Cleaved 16 Kda +25KDa
Expression Secreted by OCs Secreted by OCs
Secreted by Mφ Intracellularly in Mφ
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Posttranslational processing of TRAP 
In 1978 Lam et al., identified from a differential electrophoresis profile that TRAP 
exists in two isoforms in human serum. Two bands with different molecular weight 
were observed during electrophoresis and named as TRAP 5a and TRAP 5b165, it was 
later suggested that this phenomenon was due to the presence of sialic acid residues 
on TRAP 5a166. However, it was later discovered that the difference between TRAP 
5a and TRAP 5b was structural and was due to the presence of a flexible peptide 
loop of 20 amino acids that interacts with the active site of the enzyme and inhib-
its the reduction of the di-iron metal center preventing its enzymatic activity167,168. 
TRAP 5a can be subjected to post-translational proteolytic processing in the flex-
ible peptide loop domain by different cysteine proteinases e.g. Ctsk 169,170. The 
peptide loop has a sequence of 20 amino acids between aa 145-164, and it has 
been shown that depending on where the cut occurs, TRAP 5b will have different 
enzymatic activity171. (Figure 9) 
It was first shown in 1993 by Orlando et al. that cleavage with trypsin of a five 
amino acids sequence in the loop region resulted in the two-subunit structure, 
TRAP 5b172. Later it was investigated with cysteine proteinases and MMPs, which 
are more likely the physiological enzymes found in an OCs microenvironment. It 
was shown that the proteolytic processing of the flexible loop with cysteine pro-
teases like CtsK, L and B resulted in TRAP enzyme activation, similar (CtsK/L) 
or slightly lower (CstB) to the endogenous TRAP derived from OCs. CtsK is the 
most abundant cysteine protease in OCs and is currently the most efficient pro-
tease known to activate TRAP by proteolytical processing171. However, there are 
other as well, i.e. CstL, with an approximately the same efficient as CtsK but is 
present in non-OCs in bone171 and therefore not likely to cleave TRAP 5a in OCs. 
Di-iron center
Pepde loop
Proteases
TRAP 5a TRAP 5b
Figure 9. Proteolytic cleavage of TRAP 5a generates TRAP 5b. Proteases and/or MMPs, 
particularly CtsK in OCs, cleave the flexible peptide loop of TRAP 5a and it generates the 
TRAP 5b dimer-form stabilized by a disulphide bond. The cleavage leads to changes in the 
ferric active center increasing the phosphatase activity of TRAP 5b.
22
MMPs have also been reported to cleave TRAP to some extent, however it results 
in an inefficient enzyme activation171. Ctsk-/- mice revealed that in absence of CtsK 
another protease was compensating for its function and TRAP 5a was still cleaved to 
the same extend to TRAP 5b, but there was an accumulation of uncleaved TRAP 5a 
when was compared to the wild type170, indicating that there are different pathways 
or subpopulations of TRAP, where some TRAP is cleaved intracellularly and some 
depends on CtsK activity and accumulates. Altogether, proteolytic  cleavage by 
cysteine proteases, specially CtsK, was proposed as a mechanism for the enzyme 
activation of TRAP173.
Further studies revealed that TRAP 5a has a pH optimum of 5.0-5.2, whereas 
TRAP 5b has a pH optimum of 5.8-6.9. Moreover, TRAP 5b exhibit ~10X higher 
activity than 5a166,174,175 and a higher affinity for OPN and NPP substrates171,172. 
TRAP 5a and 5b can be separated and purified using heparin ion-exchange FPLC 
164,170,171,176,177. It was shown by Ljusberg et al., that bone TRAP derived from mouse 
and rat exhibited an elution profile with three separable peaks where the first eluted 
peak 1 represent the monomeric TRAP 5a form and major peaks 2 and 3 represent 
proteolytically cleaved TRAP 5b isoform170,171.
Using a monoclonal antibody specific for TRAP 5a, Lång et al, found that in  general, 
TRAP 5a has a broader expression pattern than TRAP 5b171,178. In particular, cells 
outside the hematopoietic lineage seem to express predominantly TRAP 5a while 
in cells derived from the hematopoietic lineage (e.g. OCs, macrophages) both 
isoforms were found to be express at different ratios.
Figure 10. Cleavage profile analysis of intra and extracellular TRAP by Heparin FPLC 
and western blot. (a) Elution profile of TRAP activity of lysate and media by MDA-C11 
cells (b) western blot analysis of Heparin FPLC elution peaks . Reprinted with permission 
of Zenger, S., Ek-Rylander, B. Biogenesis of tartrate-resistant acid phosphatase isoforms 
5a and 5b in stably transfected MDA-MB-231 breast cancer epithelial cells15. Biochimica et 
Biophysica Acta (BBA) - Molecular Cell Research. 2010;10:598-607. Copyright © Elsevier. 
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Redox activation
The redox-state in also an important regulator of TRAP enzyme activity and the 
reduction of iron ions increases also the phosphatase activity179. The TRAP active 
site contains two metal-bindings domains, coordinated by a cage of critical residues 
coordinating the catalytic center which is composed of a fixed Fe3+(ferric) and a 
redox active ion of Fe2+ (ferrous) in humans180,181. When reduced (Fe3+/Fe2+), TRAP is 
enzymatically active and when oxidized (Fe3+/Fe3+) e.g. by treatment with hydrogen 
peroxide, TRAP is enzymatically inactive182.
It was proved by Lång et al, that the enzyme activation is a two-step process, where 
the proteolytic cleavage of the peptide loop is necessary for a secondary reduction 
of the active site, and if the cleavage doesn’t occur the reduction of the enzyme is 
less efficient183.
3.2 TRAP in bone 
Studies on TRAP-/- mice showed a mild osteopetrotic phenotype with an extended area 
of metaphyseal mineralized cartilage with equal amounts of OCs that form smaller pits 
on dentine but produce equal amount of CTX fragments 169,184. Further, the TRAP-/- 
mouse have disturbed vesicular transport in OCs81. On the other hand, mice over-
expressing TRAP were mildly osteoporotic with a conflicting results between groups. 
While Angel et al., in 2000 showed a decreased trabecular density in long bones185, 
Gradin et al., in 2012 showed no difference in the  trabecular bone volume but instead 
increased BMC and BMD186. Gradin et al., also showed that TRAP expression in OB 
and OY was increased in the TRAP overexpressing mouse and that this was coupled to 
increased expression of OB markers suggesting an anabolic effect of TRAP on bone186.
3.2.1 TRAP knockout mice
The role of TRAP in bone remodeling has been elucidated by the TRAP knockout 
mice187, which nevertheless lacking TRAP activity, are not apparently sick, and viable 
under laboratory conditions. However, these mice suffer from deformity of the long 
bones and axial skeleton due to OCs defects. Both tooth eruption and development 
of skull and flat bones is normal, indicating a role of TRAP in endochondral ossifica-
tion 169. Adult TRAP KO mice have higher bone mineralization density and an increased 
cortical content, reflecting a mild osteopetrosis as early as 4 weeks of age.
The formation of OCs is normal169, however, bone resorption is defective184. 
Examination with TECM revealed that these OCs exhibit an extended area of RB 
and tend to accumulate cytoplasmic vesicles169 containing filamentous material188. 
Because the location of CtsK is normal, the accumulation of intracellular vesicles is 
probably not due to an impaired secretion. Different explanations are available, but 
none is completely proved. 1) Because the ROS function in TRAP KO is defective, 
they internalized bone degradation products and vacuoles accumulating filamentous 
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material into the cytoplasm instead of being released by transcytosis and secreted to 
blood circulation through the FSD189. 2) TRAP reduced dephosphorylating function 
modulating intracellular vesicular transport is probably impaired169.
3.2.2 TRAP localization and function in OCs
Localization and secretion 
In OCs, TRAP 5a is found in intracellular vesicles. These vesicles are then fused 
with the RB159 and TRAP 5a released into the resorption lacuna where it is cleaved 
extracellularly by CtsK to produce TRAP 5b, and consequently, is then localized 
in the RB and in the resorption lacuna171,190. 
Figure 11. Morphological characterisation of TRAP-positive vesicles in resorb-
ing osteoclasts using pre-embedding immunoEM (nanogold + silver enhance-
ment). Mouse osteoclasts cultured on dentine were processed for TEM. Positive 
labelling was identified as an organelle with at least 4 gold particles. (A&B) TRAP 
localized extracellularly to the surface of the resorption pit and along the membrane 
of the ruffled border. (C&D) TRAP-positive vesicles (arrows) were found intra-
cellularly, contained electron dense material often surrounded by a haloed region 
and single membrane. The vesicles measured about 300 nm in diameter and had a 
rounded or elongated morphology. This picture belongs to Emma McDermott thesis 
titled ‘Characterisation of the osteoclast ruffled border using advanced imaging 
thecniques’ from the University of Abeerden (2017) and hasn’t been published yet. 
Protocols for staining and sample preparation can be found there. By kind permis-
sion of E. McDermott and M.H. Helfrich, University of Aberdeen.
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Although ctsk and TRAP are confined in the same cell191, their secretion  during 
resorption seems to be different170. TRAP 5a is secreted after CtsK, suggesting 
a role for TRAP 5b in the later migration process after collagen degradation190. 
During resorption, TRAP 5b from the resorption lacuna is endocytosis and trans-
ported to the FSD domain through the transcytotic pathway, together with collagen 
degradation products.
Moreover, TRAP 5b can also be cleaved intracellularly in endosomal vesicles origi-
nating from the Golgi network170 where an intermediate form of TRAP – cleaved 
by an unknown protease- can also fuse with the transcytotic vesicles. 
TRAP as a regulator of adhesion and migration
OPN is a glycoprotein capable of mediating OC attachment to bone matrix through 
avβ3-integrin integrin192. It is the only identified in vivo substrate of TRAP, where 
TRAP 5b modulates OPN by dephosphorylation173, with functional effects on i.e. 
OCs migration41. It has been reported that OC derived from wild type, when in 
contact with TRAP dephosphorylated OPN does not induce OC attachment or 
migration192. Interestingly, OCs derived from TRAP overexpressing mice seeded 
on phosphorylated OPN showed higher migration rates than wild type OCs41. 
It has been reported that during bone remodeling the resorption area is cemented 
by a line of OPN48. TRAP 5b is coincidentally secreted in the leading edge of a 
resorptive OCs193 and can dephosphorylate OPN. In general, phosphatases have a 
repellent effect, as they are full of negatives charges, they can change the confor-
mation of the protein and affect the attachment through integrins. Some integrins 
like avβ3-integrin care about the phosphate status, but others like avβ5-integrin or 
CD44 are not affected by the phosphate status194. This implies that OCs may control 
the homing of cells to the resorption lacuna and that changes in the secretion of 
TRAP 5b can lead to different pathologies e.g. inflammation and tumor progression. 
Lastly, a genetic disease, causing loss of function in the ACP5 gene increases the 
amount of phosphorylated OPN, resulting in the autoimmune phenotype spondy-
loenchondrodysplasia (SPENCD)195, characterized by skeleton abnormalities and 
autoimmune manifestations (Details in section 3.3).
TRAP and trafficking of lysosomal enzymes
TRAP 5b has also been suggested to be responsible for dephosphorylation of 
mannose-6-P (Man-6-P) on lysosomal proteins196, a recognition marker labeled 
by the Golgi network, that marks proteins that are going to be transported to the 
lysosomes or endosomal vesicles, thus controlling vesicle trafficking. 
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Vesicular trafficking in OCs
Studies on the TRAP knockout mice169 showed a cytoplasm accumulation of 
vesicles due to a disturbance in the RB and a defective intracellular transport 
of vesicles, suggesting a novel role of TRAP in the modulation of intracellular 
vesicular transport in OCs. 
TRAP in collagen degradation (ROS)
In addition to its phosphatase activity, TRAP 5b has also been suggested to 
be involved in bone matrix degradation by producing reactive oxygen species 
(ROS)189,197,198 where TRAP 5b containing vesicles fuse with vesicles containing 
remnants from resorption and further degraded them thorough the formation of 
ROS generated by TRAP during transcytosis. 
Figure 12. Major function of TRAP as a phosphatase. TRAP may come into direct contact 
with CtsK which could proteolytically activate TRAP at its site of action. 1) OC attachment to 
the bone matrix is mediated through the interaction of the integrins (  ) and phosphorylated 
OPN ( ). TRAP 5b is able to dephosphorylate the OPN and allows the OC to move. 2) CtsK 
and MMPs are released to the resorption lacuna where TRAP 5a is processed to TRAP 5b 
by CtsK. 3) Bone degradation products (organic and inorganic) are endocytosed from the 
RB and transported in vesicles through the cell to the FSD, where they are released into the 
bloodstream. TRAP 5b can also be found intracellularly and is involved in vesicle degrada-
tion (ROS) and vesicle trafficking (via transcytosis pathway). Vesicles containing TRAP 5b 
fuse with endocytic vesicles containing bone degradation products and are degraded through 
the phosphatase reaction. TRAP 5b also dephosphorylates mannose-6-P, which is a signal for 
transporting proteins to the endosomal vesicles, recycling it.
Phosphates
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Osteoponn
Cathepsin K
MMPs
TRAP 5b
TRAP 5a
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3.2.3 TRAP as a growth and differentiation factor
Most studies analyzing the role of TRAP as a growth and differentiating factor 
have been carried out in OB, showing that TRAP is involved in OB. It was previ-
ously shown that OC-derived TRAP localized to the resorption lacuna, which may 
interact with pre-osteoblastic cells and could serve as a coupling regulator of bone 
formation, mediating the recruitment and activation of OBs186,200,202.
It has been shown in adipocytes, which are derived from the same stem cell lineage 
as OBs, that TRAP 5a, but not 5b, which is secreted by adipose tissue macrophages 
can induce hyperplastic obesity in mice203. TRAP 5a also increases differentiation 
of human adipocytes (3T3-L1) in vitro, suggesting a regulating adipogenic role of 
TRAP 5a204. It has also been shown that TRAP 5a interacts with components of 
the ECM and exhibits growth factor-like activities for pre-adipocytes and mesen-
chymal stem cells affecting its proliferation, and differentiation203,205.
3.2.4 TRAP in OBs and OYs as a coupling factor
Solberg et al., (2014) reported that TRAP containing vesicles co-localized with 
RANKL and OPG in OB vesicles206, indicating that either vesicular TRAP may 
have a role intracellularly in the vesicles or a role extracellularly where RANKL/
OPG and TRAP could be released together. This implies that TRAP has a direct role 
coupling bone resorption and bone formation during the bone remodeling process.
TRAP was shown to interact with TGFβR-interacting protein-1 (TRIP-1), an 
intracellular protein expressed in OB with high affinity for TRAP 5b, what has 
been proposed as a bridge between TGFβ and TRAP207. 
When TRIP-1 was released via exosomes to the ECM it was shown to induce 
mineralization upon binding with collagen type 1208. TRAP was shown to interact 
intracellularly with TRIP-1, activating the TβRII and inducing OB differentiation 
after resorption209. Furthermore, TRIP-1 knockdown abolished OB differentiation 
and proliferation209. 
3.2.5 TRAP as a mineralization promoter
Bone alkaline phosphatase (BALP) is a glycoprotein located to the outer surface 
of cells and matrix vesicles. It is an important component in hard tissue forma-
tion and it appears to control mineralization through regulation of the phospho-
rylated stated of OPN. It functions as a mineralization promoter by increasing 
the concentration of inorganic phosphate through dephosphorylation of OPN210. 
BALP can also inhibit the formation of mineral by decreasing the extracellular 
concentration of pyrophosphate. Both BALP and TRAP can alleviate the inhibi-
tory effect of OPN on mineralization, suggesting that TRAP could substitute for 
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alkaline phosphatase as a mineralization promoter. When the phosphatase  activity 
between BALP and TRAP was compared in vitro via dephosphorylation of bovine 
milk OPN, TRAP showed the highest activity, as it was able to remove all the 
23 phosphates of OPN211.
3.3 Proposed functions of TRAP outside bone
TRAP expression can be detected in other cell types such as neurons212, hepatocytes 
and keratinocytes15,213–215, macrophages and dendritic cells216.
TRAP in autoimmunity and inflammation
The rare recessive human genetic disease spondyloenchondrodysplasia (SPENCD) 
which is associated with short stature, skeletal sclerosis, brain calcifications and 
various forms of autoimmunity, was shown to be caused by inactivating muta-
tions in the human TRAP gene causing an increase of the ratios on phosphoryl-
ated OPN217,218. TRAP inactivation in SPENCD is associated with OPN hyper 
phosphorylation. Phosphorylated OPN is known to increase macrophage and OC 
activation through increasing the basal expression of TH1 cytokines e.g. TNF-γ 
and IL-1 and thus modulating an inflammatory response.
During inflammation, phosphorylated OPN triggers the immune system by induc-
ing macrophages, dendritic cells, monocytes and T cells to accumulate at the site 
of injury and also function as a Th1 type cytokines e.g. via stimulation of the 
CD44 co-receptor, mediating in chronic inflammation and autoimmune diseases 
like SPENCD. 
TRAP expression in phagocytic cells is associated with an enhanced bacteria clear-
ance capacity, whereas mice overexpressing TRAP had elevated levels of intra-
cellular ROS219 and macrophages lacking TRAP failed to remove phagocytosed 
bacteria187. Acp5-/- mice have also an increased basal expression of inflammatory 
cytokines such as IL-1, IL-12 and TNFα while dendritic cells lacking TRAP have 
an increased expression of IL-10 but reduced response to T-dependent antigens187,220. 
TRAP in cancer
Elevated TRAP 5b serum levels have been reported in malignant diseases involv-
ing bone e.g. multiple myeloma, bone metastasis of breast and prostate cancer163. 
TRAP has been proposed as a driver of cancer metastasis in breast cancer cells 
through regulation of CD44, an important protein implicated in the regulation of 
mesenchymal epithelial transition221. Forkhead box M1 (foxM1) is a transcriptional 
regulator of TRAP that was found to promote tumor metastasis and its presence 
indicates a poor prognosis in hepatocellular carcinoma.
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3.4 TRAP as a biomarker
TRAP 5b correlates to OC number
TRAP 5b is mainly secreted by polarized OCs and correlates to OC number/bone 
resorption, thus it correlates also to metabolic bone diseases 179,222,223.
Halleen et al., purified TRAP from human osteoclasts and they used it to produce 
a monoclonal antibody O1A against osteoclastic TRAP223. They realized that the 
antigenic properties and pH optimal for TRAP derived from OCs was identical to 
the previously isolated TRAP 5b detected in serum and it was then hypothesized 
that TRAP 5b was secreted by OCs. A strong correlation of secreted 5b with OC 
number was found in mouse224and human193 OCs cultured on plastic (i.e. non-
resorbing OCs).
It was previously described by Stepan et al. (1983), that plasma TRAP activity 
was continuously reduced after removal of parathyroid adenomas from patients 
with primary hyperparathyroidism225. Several studies have shown that changes in 
bone resorption are often associated with changes that modulate OCs numbers e.g. 
hormonal changes, treatments, and higher levels of TRAP 5b have been measured 
in postmenopausal osteoporosis163, breast and prostate cancer226 renal bone diseases, 
multiple myeloma and Paget’s disease. Moreover, TRAP 5b values can predict 
the risk of future fractures227,228. TRAP 5b loses its iron content and it is cleared 
through the liver. Therefore secreted TRAP 5b describes the amount of intact 
5b that has been secreted by OCs at a certain time reflecting the number of OC. 
TRAP 5b also correlates with OCs number in patients with autosomal dominant 
osteopetrosis type 2 (ADO2)229, various osteopetrotic rat strains229 and human OC 
cultures224. These results seem to point out that TRAP 5b is being secreted from 
OCs at a constant rate despite the resorbing activity of the cells, correlating to the 
amount of OCs but not to resorption.
TRAP 5b serum levels were found to be significantly increased in patients with 
aseptic loosening, however results didn’t correlate with CTX-I measurements, 
indicating that TRAP 5b could help to monitor cases of hip replacement for asep-
tic loosening230.
TRAP 5a as a marker of chronic inflammation
Serum TRAP 5a is highly secreted by macrophages and dendritic cells, has non-
phosphatase activity, and was considered an inactive isoform for many years. 
Nowadays its role as an inflammatory biomarker has been described in different 
pathologies. It increases its concentration in patients with chronic inflammation 
diseases such as systemic lupus erythematosus (SLE)231, rheumatoid arthritis175, 
atherosclerosis232, sarcoidosis233 and is a potential marker for disease severity in 
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cardiovascular and kidney disease cancer progression and treatment resistance234. 
Moreover, TRAP blood or serum levels are often used as a reference index for 
obesity and bone mass density (BMD)203,235 and applied to monitor breast cancer 
metastasis226 but the exactly mechanism is still not known. In metabolic bone dis-
eases 5a correlates with inflammatory markers236
3.5 Measurement of TRAP isoforms
Due to disease-specific isoform association and the different biological roles of 
TRAP 5a and 5b213,237 there is a need to measure TRAP 5a and 5b serum protein 
levels in the same sample in order to assess (1) changes in ratios of the isoforms 
and (2) correlation between different conditions and both isoforms. In a clinical 
setting, this facilitates detailed diagnosis, monitoring the severity or the develop-
ment and provides a prognosis for different conditions. Today, there are different 
TRAP assays commercially available measuring total TRAP or TRAP isoforms 
separately. Their chemistry is based either on an immuno-immobilization activity 
assays, (IIAA) capturing total TRAP or specifically TRAP 5a and then measuring 
enzyme activity at respective pH optima for the two isoforms224,238,239, or sandwich 
ELISA measuring TRAP 5a or total TRAP concentration240–242. 
For TRAP 5a, there are very specific sandwich ELISAs that are sold, but there 
are no reports of antibodies specific to TRAP 5b. TRAP 5b has been evaluated by 
measuring total TRAP and then the enzyme activity, which is proven to  measure 
OCs number243. One ELISA is the bone TRAP assay based on a pH selection (SBA-
Sciences, Oulu, Finland)242 that uses an anti-TRAP antibody, O1A, that binds the 
enzyme and the pH is then swiftly changed to pH 5.0-5.2, where the TRAP 5b 
is found to be more active. The other assay that measures TRAP activity is one 
using the selective and preferred substrate for TRAP, naphthyl ASKI phosphate244
However, the typically more abundant TRAP 5a is able to interfere in these assay 
types and this requires calculation steps to estimate the actual TRAP 5b concen-
tration245. Moreover, the redox state of the TRAP active site influences enzyme 
activity and therefore TRAP enzyme activity may not reflect the amount of TRAP 
protein in the sample. 
3.6 TRAP inhibitors
A number of TRAP inhibitors have been identified by inhibiting TRAP activity246. 
However, these kind of selective inhibitors are usually weak, toxic and lack drug-
like characteristics. Oxidizing agents such as hydrogen peroxide212 inactivate the 
enzyme via conversion of the Fe2+ ion to a Fe3+. 
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Au[bipyOMe]
Gold compounds have been used in clinics since the 70s to treat inflammatory 
conditions such as rheumatoid arthritis. However, gold is itself redox active and 
thus the gold compounds are highly unspecific inhibitors due to their oxidative 
activity. In this respect, there is a high change AubipyOMe reducing the active site 
of TRAP or acting on other proteins in the cell as well. Given that the mechanism 
of inhibition was never fully understood and several side effects were observed, 
its application was discontinued247,248. Nevertheless, its application in research as 
TRAP inhibitors is valuable. The applicability of the gold coordination compound 
AubipyOme to inhibit TRAP activity was recently shown in alveolar macro-
phages249, where it was conceptualized as an aerosol formulation to minimize the 
systemic effects of inflammation in lungs. 
Figure 13. Chemical structure of the Au(III) compound [Au(4,4′-dimethoxy-2,2′-bipyridine)
Cl2][PF6] (AubipyOMe).
5-phenylnicotinic acid 
Scwender et al. screened a series of phosphate compounds against TRAP and found 
that small compounds can inhibit TRAP by mimicking substrates250, which is the 
type of inhibitor that was used in paper IV. 5-phenylnicotinic acid (5PNA) is a 
small chemical compound of 200 Da that was found to block TRAP 5b  activity251. 
It is a competitive inhibitor that takes the place of the substrate. However if the 
activity is mediated by receptor binding it may not inhibit the activity251, although 
the binding was suggested to be at the active site through docking studies was 
never empirically tested252. 
Figure 14. Chemical structure of the 5-phenynicotinic acid (C12H9NO2)
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4  AIM OF THE THESIS
The overall aim of this dissertation was to investigate the role of TRAP isoforms 
in bone remodeling focusing on TRAP in OCs. The aim can be further sub-divided 
into the following objectives:
• In order to measure the protein levels of TRAP 5a and 5b isoforms and evalu-
ate the role of TRAP 5a in differentiation OCs, we developed an applicable 
sandwich ELISA that can detect both isoforms separately from the same sample. 
This assay allowed us to elucidate more about the role of 5a besides of being 
a precursor for TRAP 5b as well as protein levels of TRAP 5b secreted from 
in osteoclasts (Paper I).
• Investigate the relationship of TRAP isoforms and the known substrate for 5b, 
OPN, in inflammatory bone diseases and the potential application of TRAP 5a, 
5b and 5b/5a as a disease progression marker (Paper II and I). 
• Study of the heterogenetic RAW264.7 macrophage cell line and characterize a 
more stable subclone with higher capability to form TRAP positive OC-like cells 
(Paper III).
• Study the biological role of TRAP isoforms during osteoclast differentiation 
under physiological and pathological conditions by applying the small molecule 
inhibitor, 5PNA in a RANKL and IL4/IL13 –induced systems (Paper IV and I).
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5 REMARKS ON METHODOLOGY
5.1 Ethical considerations
Human peripheral blood monocytes (hPBMCs) were isolated from buffy coats 
of donated blood of healthy men at Karolinska University Hospital Laboratory, 
Huddinge, Sweden. The surplus blood products were coded for research use. All 
procedures performed in studies involving human participants were in accordance 
with the ethical standards of the Karolisnka Institutet and the Swedish Research 
Council. Written informed consent was obtained from all individual participants 
included in the study in accordance with the Helsinki Declaration.
5.2 Antibodies recognizing total TRAP and TRAP isoforms
The structural difference between TRAP 5a and TRAP 5b is the loop region present 
in 5a but absent in 5b253. Thus, it is possible to raise antibodies against TRAP 5a using 
either the loop region as immunogen or screening for TRAP 5a specific Abs raised 
against the whole TRAP 5a protein. However, it is not possible to raise TRAP 5b 
specific Abs. Therefore, in this thesis we use a combination of anti-TRAP 5a Abs 
and anti- total TRAP Abs to determine the protein concentration of the two isoforms. 
Monoclonal mouse antibodies against TRAP 5a and total TRAP was made by Mabtech 
AB, Nacka, Sweden205. Briefly, mAb against TRAP 5a was raised using the human 
loop peptide region 165 to 177 aa from the 325 aa TRAP sequence (UniProt P13686) 
as immunogen. mAb against total TRAP was raised against recombinant human 
TRAP 5a. Antibodies used for ICC, rabbit anti rat total TRAP and rabbit anti mouse 
TRAP 5a, were raised in rabbits against recombinant rat TRAP 5a and a peptide 
representing the mouse loop domain aa 167-183 in the mouse TRAP sequence (NP 
031414), respectively, by Innovagen AB, Lund, Sweden183. Specificity of TRAP 5a 
antibodies was verified using Western Blot and ELISA against TRAP 5a and 5b. 
5.3 The double TRAP 5a/5b sandwich ELISA
A previous published TRAP 5a ELISA was used as base to develop the double 
TRAP 5a/5b sandwich ELISA (Figure 15)235. The new double ELISA uses three 
antibodies: mAb 46, specific for TRAP 5a235 and mAb 25.44 recognizing both TRAP 
5a and TRAP 5b. mAb 12.56 also recognizes both isoforms, is used as a detection 
antibody and is biotinylated. The monoclonal antibody specific for TRAP 5a was 
developed using the loop present in TRAP 5a but absent in TRAP 5b due to pro-
teolytic cleavege165. In order to separate TRAP 5a from TRAP 5b, the method was 
designed as follows: In the first step, sample was added to TRAP 5a specific antibody, 
i.e. mAb 46 coated wells and TRAP 5a was captured during overnight incubation at 
+4°C and sub sequently measured using biotinylated mAb 12.56 and streptavidin 
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conjugated HRP. After overnight incubation the sample, now depleted of TRAP 5a 
but having the original amount of TRAP 5b, was transferred to wells coated with 
mAb25.44, detecting both isoforms, and the remaining TRAP 5b concentration was 
measured using biotinylated mAb 12.56- and biotin/streptavidin conjugated HRP.
Figure 15. TRAP 5a and TRAP 5b separation principle in the double TRAP 5a/5b sandwich 
ELISA. 
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5.4 RAW 264.7 cell line
The murine monocyte/macrophage cell line RAW264.7 has been extensively used 
to study bone biology as it is able to respond to RANKL and form TRAP multi-
nucleated cells, resembling osteoclast (OCs)254. RAW 264.7 was established from a 
tumor induced through injection of Abelson murine leukemia virus into a BALB/c 
mice255. RAW 264.7 cells endogenously synthesize M-CSF, hence RANKL alone 
is sufficient to drive their differentiation into OC-like cells256. RAW 264.7 has 
several advantages254, however, one disadvantage is that it is a very hetero geneous 
cell line257 than can make experiments difficult to replicate.
5.5 CD14+ monocytes isolation
We positively separated CD14+ cells based on the expression of the CD14 anti-
gen. Magnetic cell sorting of human leukocytes was used to isolate the CD14+ 
monocytes from buffy coats (see section 5.1 Ethical permits). Briefly, cells were 
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magnetically labeled with Microbeads, conjugated with a monoclonal anti-human 
CD14 antibody. CD14+ are retained in a magnetic column while the rest are 
flushed away. Later the CD14+ cells are eluded after removal of the column from 
the magnetic field.
5.6 Animal and cell models used in these projects
Mice are increasingly used in investigation of skeletal growth and regulation 
because they are biologically similar to humans. Mice can be genetically manipu-
lated, have an accelerated life span, are cost-effective and easy to breed. Similar 
to humans, murine bone physiology consists also on constant bone modelling and 
remodeling. Unlike humans, bone acquisition and bone growth continues after 
sexual maturity, which is around 6-8 weeks of age258. In mice the peak bone mass 
is achieved between 4-6 months of age258,259.
5.6.1 TRAP knock-out mice
TRAP-deficient mice were generated by Allison Hayman and Timothy Cox184 in 
collaboration with Martin Evans at Cambridge University. Mice were provided by 
Paul Saftig’s lab from Kiel Universität to Arne Egesten from the University of Lund. 
ACP 5-/- are not apparently sick, they present short limbs, and white teeth, probably 
due to over mineralization, are mildly osteopetrotic and have lost hearing169,260.
We used female and male mice that were 7-11 weeks of age at the start of the 
experiment.
5.6.2 C57BL/6N mice
Inbreed strains of mice, such as C57BL/6N mice, originally from Charles River 
Laboratories, Germany, allow for genetic uniformity of each animal, allowing repro-
ducible results with smaller samples sizes. Breeding was done in the Facilities of 
Sahlgrenska Academy Institute of Medicine, University of Gothenburg by Professor 
Ulf Lerner and Petra Henning. We used male mice that were 8-12 weeks of age 
for isolation of bone marrow macrophages from femur and tibia 
We used CD45.1+ on C57BL/6 genetic background, donated from Hong Qian, 
Karolinska University as a control for the TRAP knock out mice. Mice used were 
between 8-11 weeks.
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6 RESULTS AND DISCUSSION
6.1 Paper I 
Aim
In this paper we aimed to develop a human TRAP 5a and 5b isoform specific ELISA 
that would give the possibility of quantifying separately TRAP5a and TRAP 5b 
protein levels in different types of samples i.e. serum, cell culture media and cell 
lysate. This human TRAP 5a and 5b isoform specific ELISA was then used to 
investigate TRAP 5a/5b levels and correlations in healthy men (paper I) as well 
as production and secretion of TRAP 5a/5b in in vitro cultured OCs (paper IV).
Double TRAP 5a/5b sandwich ELISA development
We were able to develop a double TRAP5a/5b sandwich ELISA that can be used 
to measure human TRAP 5a and 5b protein levels in serum, cell culture media and 
cell lysate. However, in serum, TRAP is found in complex with alpha 2 macro-
globulin (a2M), which affects the composition of the active site261 and loop region 
i.e. the antigen binding part of TRAP 5a. We therefore hypothesized that serum 
TRAP 5a would not bind efficiently to mAb46, as has been shown for the TRAP 5a 
ELISA235 and that this would result in low TRAP 5a detection on mAb46 and a 
consequent higher TRAP 5b measurement on the mAb25.44 due to high TRAP 5a 
carry-over. When serum samples were pre-treated in order to change the pH and 
allow any complex involving TRAP to disassociate, TRAP 5a detection increased 
and TRAP 5b detection was decreased, being more similar to previously reported 
TRAP isoforms measurements262. 
Figure 16. Measurement of TRAP 5a secretion from CD14+ cells induced with RANKL 
and M-CSF. A) cells cultured on plastic secrete both isoforms from day 4 C) TRAP isoforms 
secreted when cells are cultured on bone slices. There is a delay in TRAP secretion being 
significant vs when cultured on plastic.
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Validation of the TRAP 5a/5b double ELISA showed that parameters e.g. inter- 
and intra-assay variations were within acceptable ranges, however, when/if the 
ELISA is subject for commercialization/diagnostic use in laboratories, validation 
in accordance with the FDA guidelines for method validation, “Bioanalytical 
Method Validation Guidance for Industry” will be applied.
TRAP 5a and 5b protein in serum from healthy men and correlation to CTX-I
In previous studies, human serum, TRAP 5a and 5b protein have been separated 
by chromatography, identified by electrophoresis and quantified by a specific 
ELISA223 . These studies showed that TRAP 5a accounted for 87% of the enzyme 
protein but 55% of total the activity262. Separation with chromatography showed 
that serum TRAP consisted of ~87% and TRAP 5b ~13%262. This is comparable 
to 75% vs 25% for TRAP 5a and 5b protein in human serum measured with the 
double-TRAP 5a/5b sandwich ELISA.
In serum from heathy men, there was a positive correlation between TRAP iso-
forms 5a and 5b. Surprisingly, not only 5b, but also 5a correlated positively to 
resorption marker CTX-I. This suggests that both isoforms are secreted from dif-
ferentiating OCs during normal bone turnover. However, 5a is also derived from 
other sources e.g. macrophages and the positive correlation with CTX-I seen here 
in serum from healthy individuals likely indicates that the part of 5a derived from 
non-OC sources is constant. In an individual in a pathological state, e.g. inflam-
mation, the pool of 5a originating from other sources is likely to be affected and 
therefore the correlation with CTX-I might disappear. 
It was observed that the TRAP isoforms in serum correlate with the resorption 
marker- Collagen type-I C-terminal fragment (CTX) in healthy individuals (paper I), 
while in case of inflammatory conditions TRAP5a has been shown to correlate 
with certain inflammatory markers e.g. YKL-40 and IgM RF but not with the 
resorption markers in TRAP 5a have not been studied before263. In pathological 
situation i.e. anorexia, the correlation between TRAP 5a and TRAP 5b is lost, and 
could indicate a sign of a pathological bone disorder264. Both tartrate-resistant acid 
phosphatase isoforms 5a and 5b are secreted by differentiating osteoclasts and 
correlate with serum levels of CTX-I in men.
Distribution of TRAP 5a and 5b in in vitro cultured OCs
TRAP activity staining confirmed the appearance of multinucleated TRAP positive 
cells with varying activity levels. By ICC, TRAP 5a specific staining was apparent 
in many of the multinucleated and mononuclear cells, while total TRAP signal was 
lower in larger multinucleated cells, indicating effective secretion of the TRAP 
5b isoform. A few mononuclear cells stained double positive for both isoforms, 
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indicating that TRAP processing starts already at a late mononuclear stage and 
could be a marker for mononuclear pre-OCs and since it is, produce it could have 
a role in the mononuclear pre-osteoclasts.
Production and secretion of TRAP 5a and 5b from in vitro cultured OCs
There is a common perception that TRAP is secreted by OCs as TRAP 5a, later is 
proteolytically processed extracellularly by e.g. CtsK to produce TRAP 5b, before 
being endocytosed, and transported through the OC in transcytotic vesicles where 
is finally secreted through the FSD domain15. However, data obtained here showed 
that secretion of both TRAP 5b as well as TRAP 5a isoform was progressively 
increasing, although 5b dominated. Overall it indicates that OCs contribute to 
TRAP 5a levels in serum, where it was previously indicated that only macrophages 
and dendritic cells contributed.
Further, both isoforms were also present in cell lysate before either of the isoforms 
was observed in medium, further establishing that 5b can be formed intracellular 
in OCs where TRAP 5b may have a role in mononuclear pre-OCs, although it is 
not clear if this pool of 5b can also be secreted from OCs15.
Conclusion
• A new double TRAP 5a/5b sandwich ELISA measuring TRAP 5a and 5b protein 
in the same sample was developed and verified for use with serum, cell culture 
media and cell lysate. The difference observed with this new TRAP 5a/5b 
sandwich previously published IIAAs shows the importance of measuring 
TRAP 5a and 5b protein. 
• In vitro cultured OCs produce and secrete both TRAP 5a and 5b. TRAP 5a 
and 5b correlate to each other in both serum from healthy males and in vitro 
cultured OCs. TRAP 5a correlates to CTX-I in both healthy males and in vitro 
cultured OCs on cultured on bone. This suggests that a considerable proportion 
of serum TRAP 5a originates from OCs and that it might show an undiscovered 
regulatory mechanism between bone resorption and bone remodeling. 
6.2 Paper II 
Aim
The aim was to assess the relation of OPN phosphorylation with TRAP 5a and 
5b protein in OA and RA joint tissues, in order to possible distinguish differences 
between these different diseases characterized by cartilage and bone destruction
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Phospho-OPN and TRAP in synovial fluid
Full-length OPN was higher in RA+/- patients compared to OA patients. This was 
also true for phosphorylated C-terminal end of OPN fragment.
It was possible to detect TRAP 5a and TRAP 5b protein in synovial fluid although 
two patients had undetectable TRAP 5b levels. TRAP 5a was higher in RA+ 
compared to RA- and OA, while TRAP 5b was higher in OA compared to RA+/- 
groups. However, total TRAP was the same in all three groups.
Interestingly, the TRAP 5b/5a ratio was higher in OA compared to RA and it cor-
related negatively to the amount of phosphorylated OPN i.e. the less TRAP 5b the 
more phosphorylated OPN. This is probably due to the high individual variation.
Conclusions
• It is possible to use the double TRAP 5a/5b sandwich ELISA to measure TRAP 
5a and 5b protein in synovial fluid.
• Analysis of the TRAP 5b/5a ratio was more sensitive than measuring TRAP 
5a and 5b alone in establishing differences between the different groups.
• Decreased ratio of TRAP 5b/5a in RA patients was associated with an increased 
amount of phospho-OPN strengthening previous data showing that OPN is an 
vivo substrate for TRAP 5b.
6.3 Paper III
Aim
The aim of this study was to isolate RAW 264.7 clones more specifically destined 
to form OC-like cells and clones with a low ability to form OC-like cells. In addi-
tion, the study aimed to investigate why RAW264.7 have different capacity to form 
OC-like cells and understand the hallmarks of decision points in differentiation of 
these cells to OC or macrophage direction. 
Selection of subclones
First, subclones were isolated from RAW 264.7 parental cells by single cell clon-
ing, two clones, H9.2d5 (alias H9) and J8.2g6 (alias J8), were selected for further 
analysis based on the expression levels of two OC markers, TRAP and CtsK. H9 
exhibit high TRAP and CtsK mRNA expression while J8 had very low mRNA 
expression of both these markers. 
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H9, but not J8, can form OCs in vitro on plastic and bone
RANKL treated subclone H9 had a variety of OC related features i.e. increased 
acidification, pit formation and CTX-I formation. On the other hand, phagocyto-
sis, a macrophage characteristic, were decreased. RANKL treated H9 also exhib-
ited increased gene expression of OC target genes i.e. TRAP, ctsk, OC-STAMP, 
ATP06vd2 and ATP6i. On the other hand, subclone J8, did not seem to be able to 
exhibit any typical OC characteristic. 
H9 forms OCs faster than RAW 264.7 due to higher nuclear translocation of Nfatc1
Interestingly, H9 formed OC-like cells faster than parental RAW 264.7 cells although 
their capacity to function as OC-like cells did not differ after 4 days of RANKL-
treatment. Gene expression analysis revealed that unstimulated H9 express higher 
levels of OC master transcription factor NFATc1 compared to RAW 264.7. NFATc1 
ICC further revealed that nuclear translocation in H9 is higher suggesting that H9 
therefore more efficient in rapid expression of OCs related genes. 
Conclusion
• Sub-clone H9 is more homogenous and committed OC precursor than the 
general RAW 264.7 cells.
• RANKL differentiation of H9 results in rapid formation of OCs with features 
like multinucleation, TRAP+, demineralization, pit formation and collagen 
degradation.
• The rapid formation of OCs using H9 is due to increased gene expression and 
nuclear translocation of NFATc1 already in unstimulated H9. This could be 
especially valuable in initial larger screening experiments but also later in the 
scientific process i.e. to study osteoclastogenesis.
6.4 Paper IV
Aim
The aim was to study the role of TRAP 5b in OC differentiation. For this, we 
used a previously characterized TRAP 5b inhibitor, named 5-phenylnicotinic acid 
(5PNA)251 that was shown to prevent the activation of the active center of TRAP 
5b, thus rending the enzyme inactive. We examined how the inhibitor affects the 
differentiation of monocytes under RANKL and IL-4/IL-13 conditions, mimick-
ing physiological and inflammatory conditions, respectively.
Toxicology studies
In order to evaluate whether the inhibition of osteoclastogenesis was due to a toxic 
effect we measured the metabolic activity based on the release of intracellular ATP 
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of hPBMCs treated with increasing concentrations of 5PNA (0-400 µM) and we 
found out that 5PNA was not toxic up to 200 µM and didn’t induce morphologi-
cal effects on the cells.
Inhibition of TRAP 5b inhibits OC differentiation
We observed a decrease in the number of OCs, and the ones that did differentiate 
appeared to be smaller than in the controls. We used a structurally unrelated TRAP-
inhibitor Au[bipyOMe]249 and could see a similar tendency although the effect 
was less pronounced (Figure 1A), suggesting a role for TRAP in OCs formation.
Inhibition of TRAP 5b affects the transcription of OC markers
We examined the expression of OC markers upon 5PNA treatment in RANKL-
induced induced human and mouse monocytes .We noticed that NFATc1 was 
downregulated in both human and mouse in response to the treatment. CtsK was 
consequently decreased in both human and mouse as NFATc1 coordinates the 
expression of several OC markers. We measured RANK expression in human 
monocytes and it showed a tendency in reduction. This suggests that 5PNA or 
TRAP 5b could be affecting early stages of osteoclastogenesis, for example affect-
ing RANKL fusion regulators, thus preventing the OCs to form.
TRAP 5b inhibition affects resorption
As was previously shown by others, IL-4/IL-13-induced monocytes were not 
able to resorb bone but only the RANKL-induced ones could degrade the colla-
gen type. It has been previously reported that TRAP knockout mice have OCs in 
vivo and when inhibiting TRAP and despite the lower resorption measurements 
after 5PNA, some cells were able to differentiate into OCs and resorb bone. The 
number of differentiated OCs was less and the resorption was consequently lower. 
However, it also seemed to be more bone resorbed underneath osteoclasts treated 
with 5PNA. We would need to measure the resorbed area and CTX in order to 
substantiate this observation. One possible explanation could be that the OCs can’t 
migrate as fast in the presence of 5PNA and remain anchored for longer time to 
the same resorption pit.
TRAP 5a and 5b OCs production are altered after 5PNA in RANKL-induced OCs
The 5PNA treatment decreased the secretion of TRAP 5b but did not affect TRAP 
5a secretion. TRAP 5b production seems to be decreased while TRAP 5a produc-
tion shows a decrease tendency levels in both lysate and medium. The observed 
difference was more pronounced in lysate, but no apparent difference was detected 
in trafficking of TRAP (Figure 3). However, the 5PNA treated cells did generate 
TRAP isoforms, albeit slower than the untreated cells. Therefore, we concluded 
that the TRAP-inhibition did not disallow OCs differentiation, but reduced the 
efficiency of the process.
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5PNA affects fusion of RANKL-induced but not in IL4/IL-13 – induced in 
hPBMCs and mBMMs
To examine whether TRAP 5b is involved in fusion and therefore could be a reason 
for the delayed differentiation of OCs and impaired overall resorption capacity, 
we stimulated PBMCs with IL-4 and IL-13 in order to form foreign body giant 
cells (FBGCs). These cells compared to the RANKL-induced produced equal 
amounts of TRAP 5a but significantly lower levels of TRAP 5b, and therefore, 
provide a control for TRAP 5b inhibition. It has been shown before that IL-4 is 
able to mediate fusion of monocytes by stimulating expression of DC-STAMP131. 
Moreover, it was also shown that IL-4 inhibits RANKL-stimulated osteoclast 
formation and large multinucleated TRAP positive cells are formed134. In PBMCs 
stimulated with IL-4 and IL-13, the fusion was unchanged with 5PNA treatment, 
furthermore the treatment showed a tendency in TRAP 5a secretion up to 50uM. 
This was  different from the RANKL stimulated PBMCs, indicating that with the 
IL stimulation under 5PNA treatment the CD14+ monocytes are still able to fuse. 
IL-4 was shown to block RANKL pathway, and they can use another set of mol-
ecules to fuse134. 
Conclusions
• With the TRAP activity inhibitor, we were able to show that TRAP activity 
was indeed promoting OC differentiation under RANKL stimulation.
• TRAP inhibitor did not seem to have an effect under interleukin stimulation. 
• It seems that the TRAP inhibitor initially affects or delays the clustering of 
the monocytes in aggregates that eventually fuse into multinucleated OC on 
plastic. Also on bone, it looked like there are more monocytes remaining that 
did not form multinucleated OCs. 
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7 CONCLUDING REMARKS
1) The development of a novel TRAP 5a/5b ELISA allowed us to study the expres-
sion and secretion of the isoforms during OCs development, and show that 
OCs also secrete TRAP 5a under RANKL-induced conditions. Moreover, both 
isoforms were found to correlate to bone resorption marker, CTX-I, indicating 
that TRAP 5a levels can be used to study bone remodeling.
2) We studied the expression of TRAP 5a and 5b under inflammatory conditions, 
in patients with RA and OA and found out that the ratio 5b/5a determines the 
phosphorylated status of OPN, which contributes to a vicious cycle of inflam-
mation, recruiting inflammatory cells, and leading to cartilage degradation and 
bone destruction. 
4) Paper III was a methodological paper, were we showed that the RAW264.7 
cells be used for screening purposes as they can form TRAP positive cells, 
acidify and resorb bovine cortical bone. The H9 clone form TRAP positive 
cells quicker than the parental RAW 264.7, possible because this clone is in a 
more differentiated stage, and allow to more stable results.
3) We have studied the biological role of TRAP in differentiating OCs, and we 
hypothesized that TRAP promotes RANKL-induced osteoclast differentiation 
in vitro, and is necessary for a normal resorption. However, it did not affect 
the formation of FBGCs. 
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8 FUTURE PERSPECTIVE AND CLINICAL 
SIGNIFICANCE
Bone remodeling is essential for a healthy skeleton, and imbalances in the resorp-
tion or formation of bone are known causes of several skeletal diseases. Knowing 
more about how osteoclastogenesis is regulated is essential for being able to pro-
pose new therapies. In the mark of this, the double TRAP 5a/TRAP 5b ELISA 
gives the possibility to redo everything that has been done before. We could better 
understand the role of TRAP 5a and TRAP 5b in different diseases, and possible 
give a better comprehension of the overall function of TRAP, as it has been prob-
ably masked by the fact that it was impossible to measure the protein content of 
it before, a redox status were affecting the overall TRAP activity. 
TRAP 5b/5a ratio was shown to correlate with the phosphorylation status of OPN, 
but it could also correlate with several other prognosis markers in different bone 
diseases, Local supplementation of TRAP 5b in clinical trials could be a possibil-
ity. It seems interesting to evaluate 5a/5b ratios since it seems to be more sensitive 
for evaluation of the bone remodeling status for diagnostic purposes264. We show 
that lower levels of TRAP 5b/TRAP 5a correlated with a higher phosphorylated 
statues that could contribute to the inflammation cycle.
The identification of clones with different OC related makers from the RAW 264.7 
cell line, that show different capabilities to form TRAP positive cells, indicates 
that this heterogenetic population can be sorted using these markers, so the high 
variability in the RAW 264.7 could be solved by sorting the cells based on NFATc1 
and CtsK expression previous treatment with RANKL. These findings could 
be also applied in human monocytes in order to gather a uniform population of 
cells. It would be interesting to use the H9 in a high throughput system, search-
ing for new OC inhibitors, as it represents a more stable and faster system than 
the RAW 264.7 parental. Resolving monocyte heterogeneity and understanding 
how their functional identity is determined holds great promise for therapeutic 
immune modulation
TRAP has been shown to be a real hallmark in osteoclastogenesis. In vivo studies 
are necessary to further understand how 5PNA affects bone remodeling. Study if 
treatment with TRAP 5b could rescue the phenotype in the ACP5-/- mice, could 
be a good strategy. 
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Lastly, although it was not studied in this thesis, but to understand the expression 
of TRAP in other bone cells seems necessary to comprehend the whole picture 
of TRAP in the bone remodeling unit. The role of TRAP in different bone cells, 
different from OCs seems, like the OBs an interesting subject for research behind 
the goal of understanding bone remodeling and improve therapy for several bone 
diseases. 
The functional significance of a heterogeneous OC population still remains to be 
elucidated, and is an important goal to understand how a physiological or a patho-
logical state could modulate OCs differentiation and their functions e.g. resorp-
tion9,265. The implications of site-specific OCs may be significant, especially when 
considering novel treatment options to inhibit resorption.
46
9 ACKNOWLEDGEMENTS 
The work presented in this thesis was financially supported by grants from the 
Swedish Research Council and the Marie Curie Euroclast Consortium.
There are many people I owe my thanks to and I know it would not have been 
possible to finish this thesis without all of them. I feel extremely lucky to have 
met all these incredible people and would like to tell you that you have made this 
PhD journey a blast!
First and foremost, I would like to thank my main supervisor Pernilla Lång and 
my co-supervisors Göran Andersson and Tuomas Näreoja. Pernilla, thanks for 
having the patience to teach me so many things in the lab and for the interesting 
and fun scientific discussions. Thanks for helping me develop as a researcher, for 
supporting and encouraging me to find focus every time it was lost, I admire your 
love for science and I can not say how much I learned from you. Göran, thank you 
for giving me the opportunity to be part of your group, for continuously inspiring 
me with your enthusiasm for science and bright ideas and for the fun we had dur-
ing the meetings around Europe. Tuomas, thanks for being my third supervisor, 
for encouraging me to try new things and teaching me so much not only about 
science but about how to deal with the scientific community. I had also a lot of 
fun arranging the world in our discussions. 
To the members of my group, a big thank you to Maria Norgård, Barbro 
Ek-Rylander and Sara Windahl for all the good meetings and feedback. To the 
ex members of my group, Christina Patlaka and Anja Reithmeier, I do not know 
where I would be without you. Both of you supported me when I needed it the 
most, mentored me though scientific advice every time I asked for it and you help 
me to establish in Stockholm. However, what I value the most it is your friendship 
and your warm when I needed it the most. And of course the beers shared! Anh 
N Tran, I met you before I started this journey at the very first Euroclast meeting 
(through Skype), and our friendship has only gone bigger since then! You are a 
great scientist, with a bright mind and you have rendered yourself very important 
in my life lately! Suchita Desai, I enjoyed working with you during your master 
thesis, and I was happy to see that you were starting your PhD with Tuomas. I 
have had a lot of fun sharing time with you!
To my office colleagues/friends and former coworkers, Magali Merrien you and 
Teresa Seestern were the first people I started to hang out with, Teresa left, but we 
still talk here and then, and Magali has always been there for me, you are a very 
special person with a big heart and a great personality! Joman Javadi, Zurab 
Bzhalava, Sara Arroyo, Mihaela Zabulica, Rim Jawad, Martin Lord, Arun 
Selva, Antje Zickler, Raghu Chittoor, Ashish Singh, and all the students that 
47
 
 
 
know that whenever I felt down you would lighten me up.
there, thank you for waiting for me. You have no idea how comforting was to 
my friend and my love for your endless support, motivation and for always being 
Finally, I consider myself the luckiest person to have met you, Pep, my partner, 
because you all are cute and necessary, and life is better with you.
after my demands! To my nephews, Mateu, Jordi, and also to my son Roger 
knowing about my research, especially thanks to my aunt Victoria for looking 
a faltar i tindre’t a prop! To the rest of my family for always being interested in 
reach out as far as I wanted and could. To my brother Jaume, perque et trobe molt 
To my parents, Teresa and Rafel, for always supporting and encouraging me to 
Andrea, per sempre tindre temps. And I can’t forget all the Cartaginenses.
Cristina, Sina and Aitor, per fer-me vore que la distancia no era tan gran. And 
brunchs y por vuestra amistad! To my hometown friends, especially Estefania, 
Patricia Gonzalez and Lorena Galan, gracias por estar ahi siempre, por los 
To all the friends I got in Stockholm, especially the ones imported from Valencia, 
with us and for the osteoclast discussions.
pictures! And to all the supervisors, thanks for your input, sharing your experience 
an extra thank you to Emma McDermott and Miep Helfrich for the beautiful 
Segeletz, Henrik Lövfall, Vikté Lionikaité, Yixuan Cao, Arjen Gebraad and 
whiskies, and food! Giuliana Ascone, Sara Sprangers, David Massa, Sandra 
all the discusions about osteoclasts, about our projects, about our PhD, about beers, 
To all Euroclast partners, this got to an end but the journey was worth it, I enjoyed 
cism at divisional seminars.
To the rest of the division and to all PIs and seniors, for they constructive criti- 
how to send the application and also for always sharing your smile with all of us. 
was needed. To Mia Bjerke, because without you I would be still figuring out 
thank you also to Agata Wasik for the advices and for always being there when 
fun I had all these years and how lucky I have been to share time with you. Special 
have been part of the division, I would have to write 10 pages to say how much 
48
10 REFERENCES
1. Currey JD. Bones. Structure and mechanics. Princeton, NJ: Princeton 
University Press 1, (2002).
2. Lanyon, L. E. & Baggott, D. G. Mechanical function as an influence on the 
structure and form of bone. J. Bone Joint Surg. Br. 58–B, 436–443 (1976).
3. Turner, C. H. Bone strength: Current concepts. Ann. N. Y. Acad. Sci. 1068, 
429–446 (2006).
4. Seeman, E. Structural basis of growth-related gain and age-related loss of 
bone strength. Rheumatology 47, 2–8 (2008).
5. DiGirolamo, D. J., Clemens, T. L. & Kousteni, S. The skeleton as an endo-
crine organ. Nat. Rev. Rheumatol. 8, 674–83 (2012).
6. Langdahl, B., Ferrari, S. & Dempster, D. W. Bone modeling and remodeling: 
potential as therapeutic targets for the treatment of osteoporosis. Ther. Adv. 
Musculoskelet. Dis. 8, 225–235 (2016).
7. Martini FH, Ober, W. Fundamentals of anatomy and physiology. (2001).
8. Watson, E. C. & Adams, R. H. Biology of Bone: The Vasculature of the Skeletal 
System. Cold Spring Harb. Perspect. Med. a031559 (2017). doi:10.1101/
cshperspect.a031559
9. Everts, V., de Vries, T. J. & Helfrich, M. H. Osteoclast heterogeneity: Lessons 
from osteopetrosis and inflammatory conditions. Biochim. Biophys. Acta – 
Mol. Basis Dis. 1792, 757–765 (2009).
10. Scott, C. & Hightower, J. The matrix of endochondral bone differs from the 
matrix of intramembranous bone. Calcif Tissue Int 49, 349–54 (1991).
11. Crockett, J. C., Rogers, M. J., Coxon, F. P., Hocking, L. J. & Helfrich, M. H. 
Bone remodelling at a glance. J. Cell Sci. 124, 991–8 (2011).
12. Segeletz, S. & Hoflack, B. Proteomic approaches to study osteoclast biology. 
Proteomics 16, 2545–2556 (2016).
13. Ryu, J. et al. Sphingosine 1-phosphate as a regulator of osteoclast differentia-
tion and osteoclast-osteoblast coupling. EMBO J. 25, 5840–5851 (2006).
14. Boyce, B. F. F. Advances in the Regulation of Osteoclasts and Osteoclast 
Functions. J. Dent. Res. 92, 860–867 (2013).
15. Zenger, S. Biogenesis of tartrate-resistant acid phosphatase isoforms 5a and 
5b in cell and animal models Serhan Zenger. (2010).
49
16. Hofbauer, L. C. et al. The roles of osteoprotegerin and osteoprotegerin ligand 
in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15, 2–12 
(2000).
17. Takahashi, N., Udagawa, N., Udagawa, N. & Suda, T. Vitamin D endocrine 
system and osteoclasts. Bonekey Rep. 3, 495 (2014).
18. Capulli, M., Paone, R. & Rucci, N. Osteoblast and osteocyte: Games without 
frontiers. Arch. Biochem. Biophys. 3, (2014).
19. Puzas JE, I. M. Osteoblast/osteoclast coupling. In: Rifkin BR, Gay CV Biol. 
Physiol. Osteoclast. CRC Press. Boca Raton, FL, USA, pp. 337–356 (1992).
20. Lerner, U. H. Osteoclast formation and resorption. Matrix Biol. 19, 107–120 
(2000).
21. Wu, M., Rementer, C. & Giachelli, C. M. Vascular calcification: an update 
on mechanisms and challenges in treatment. Calcif. Tissue Int. 93, 365–73 
(2013).
22. Sisay, M., Mengistu, G. & Edessa, D. The RANK/RANKL/OPG system in 
tumorigenesis and metastasis of cancer stem cell: potential targets for anti-
cancer therapy. Onco. Targets. Ther. Volume 10, 3801–3810 (2017).
23. Lindberg, M. K. et al. Estrogen receptor alpha, but not estrogen receptor beta, 
is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor 
activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. 
J. Endocrinol. 171, 425–33 (2001).
24. Sekine, C. et al. Differential regulation of osteoclastogenesis by Notch2/
Delta-like 1 and Notch1/Jagged1 axes. Arthritis Res. Ther. 14, R45 (2012).
25. Ashley, J. W. et al. Notch signaling promotes osteoclast maturation and resorp-
tive activity. J. Cell. Biochem. 116, 2598–2609 (2016).
26. Eriksen, E. F. Cellular mechanisms of bone remodeling. Rev. Endocr. Metab. 
Disord. 11, 219–227 (2010).
27. Everts, V. et al. The bone lining cell: its role in cleaning Howship’s lacunae 
and initiating bone formation. J. Bone Miner. Res. 17, 77–90 (2002).
28. Sims, N. A. & Vrahnas, C. Regulation of cortical and trabecular bone mass 
by communication between osteoblasts, osteocytes and osteoclasts. Arch. 
Biochem. Biophys. 561C, 22–28 (2014).
29. Bakker, A. D. & Everts, V. Osteocytes and osteoclasts, a relationship under 
strain. Clin. Rev. Bone Miner. Metab. 12, 14–26 (2014).
50
30. Nango, N. et al. Osteocyte-directed bone demineralization along canaliculi. 
Bone 84, 279–288 (2016).
31. Bonewald, L. F. & Johnson, M. L. Osteocytes, Mechanosensing and Wnt 
Signaling. Bone 42, 606–615 (2008).
32. Bonewald, L. F. Osteocytes as dynamic multifunctional cells. Ann. N. Y. Acad. 
Sci. 1116, 281–290 (2007).
33. Staines, K. A., MacRae, V. E. & Farquharson, C. The importance of the 
SIBLING family of proteins on skeletal mineralisation and bone remodelling. 
J. Endocrinol. 214, 241–255 (2012).
34. Zenger, S., Ek-Rylander, B. & Andersson, G. Long bone osteoclasts display an 
augmented osteoclast phenotype compared to calvarial osteoclasts. Biochem. 
Biophys. Res. Commun. 394, 743–9 (2010).
35. Flores, M. E., Norgård, M., Heinegård, D., Reinholt, F. P. & Andersson, G. 
RGD-directed attachment of isolated rat osteoclasts to osteopontin, bone 
sialoprotein, and fibronectin. Exp. Cell Res. 201, 526–530 (1992).
36. Stein, H., Perren, S. M. & Mosheiff, R. New Insights into the Biology of 
Osteocalcin Meredith. Orthopedics 27, 915–918 (2004).
37. Lund, S. A., Giachelli, C. M. & Scatena, M. The role of osteopontin in inflam-
matory processes. J. Cell Commun. Signal. 3, 311–322 (2009).
38. Castello, L. M. et al. Osteopontin at the Crossroads of Inflammation and 
Tumor Progression. Mediators Inflamm. 2017, (2017).
39. Luukkonen, J. et al. Osteoclasts secrete osteopontin into resorption lacunae 
during bone resorption. Histochem. Cell Biol. 151, 475–487 (2019).
40. Bellahcène, A., Castronovo, V., Ogbureke, K. U. E., Fisher, L. W. & Fedarko, 
N. S. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): 
Multifunctional proteins in cancer. Nat. Rev. Cancer 8, 212–226 (2008).
41. Ek-Rylander, B. & Andersson, G. Osteoclast migration on phosphorylated 
osteopontin is regulated by endogenous tartrate-resistant acid phosphatase. 
Exp. Cell Res. 316, 443–451 (2010).
42. Holt, C., Sørensen, E. S. & Clegg, R. A. Role of calcium phosphate nano-
clusters in the control of calcification. FEBS J. 276, 2308–2323 (2009).
43. Boyce, B. F., Rosenberg, E., de Papp, A. E. & Duong, L. T. The osteoclast, 
bone remodelling and treatment of metabolic bone disease. Eur. J. Clin. Invest. 
42, 1332–41 (2012).
51
44. Sims, N. A. & Martin, T. J. Coupling signals between the osteoclast and 
osteoblast: How are messages transmitted between these temporary visitors 
to the bone surface? Front. Endocrinol. (Lausanne). 6, 1–5 (2015).
45. Raggatt, L. J. & Partridge, N. C. Cellular and molecular mechanisms of bone 
remodeling. J. Biol. Chem. 285, 25103–25108 (2010).
46. Frost, H. M. Tetracycline-based histological analysis of bone remodeling. 
Calc. Tissue Res. 3, 211–237 (1969).
47. Sims, N. a & Martin, T. J. Coupling the activities of bone formation and 
resorption: a multitude of signals within the basic multicellular unit. Bonekey 
Rep. 3, 1–10 (2014).
48. Nicolai Ernlund Lassen, Thomas Levin Andersen, Gro Grunnet Pløen, Kent 
Søe, E. M. H. & Søren Harving, Gete Ester Toft Eschen, and J.-M. D. Coupling 
of bone resorption and formationin real time: new knowledge gained from 
human haversian BMUs. J. Bone Miner. Res. 32, 1389–1390 (2017).
49. Milone, F. et al. Assessment and clinical implications of RANK/RANKL/
OPG pathway as markers of bone tumor progression in patients with NET 
harboring bone metastases. Biomarkers Biochem. Indic. Expo. response, 
susceptibility to Chem. 18, 121–125 (2013).
50. Lafage-Proust, M.-H. et al. Assessment of bone vascularization and its role 
in bone remodeling. Bonekey Rep. 4, 1–11 (2015).
51. Sims, N. a & Martin, T. J. Coupling the activities of bone formation and 
resorption: a multitude of signals within the basic multicellular unit. Bonekey 
Rep. 3, 1–10 (2014).
52. Bodine, P. V. Wnt Signaling in Bone. 4, 108–123 (2007).
53. Clevers, H. Wnt/β-Catenin Signaling in Development and Disease. Cell 127, 
469–480 (2006).
54. Baron, R. & Kneissel, M. WNT signaling in bone homeostasis and disease: 
from human mutations to treatments. Nat. Med. 19, 179–192 (2013).
55. Day, T. F., Guo, X., Garrett-Beal, L. & Yang, Y. Wnt/β-catenin signaling in 
mesenchymal progenitors controls osteoblast and chondrocyte differentiation 
during vertebrate skeletogenesis. Dev. Cell 8, 739–750 (2005).
56. Li, X. et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt 
 signaling. J. Biol. Chem. 280, 19883–19887 (2005).
57. Niehrs, C. Function and biological roles of the Dickkopf family of Wnt modu-
lators. Oncogene 25, 7469–7481 (2006).
52
58. Lind, T. et al. Vitamin A is a negative regulator of osteoblast mineralization. 
PLoS One 8, e82388 (2013).
59. Lind, T. et al. Excessive dietary intake of Vitamin A reduces skull bone thick-
ness in mice. PLoS One 12, 1–15 (2017).
60. Khosla, S. Minireview: The OPG/RANKL/RANK System. 142, 5050–5055 
(2001).
61. Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis 
through RANKL expression. Nat. Med. 17, 1231–1234 (2011).
62. Ikebuchi, Y. et al. Coupling of bone resorption and formation by RANKL 
reverse signalling. Nature 561, 195–200 (2018).
63. Martin, T. J. & Sims, N. A. Osteoclast-derived activity in the coupling of bone 
formation to resorption. Trends Mol. Med. 11, 76–81 (2005).
64. Sims, N. A. & Martin, T. J. Osteoclasts Provide Coupling Signals to Osteoblast 
Lineage Cells Through Multiple Mechanisms. Annu. Rev. Physiol. 82, 1–23 
(2020).
65. Karsdal, M. a. et al. Transforming Growth Factor-β Controls Human 
Osteoclastogenesis through the p38 MAPK and Regulation of RANK 
Expression. J. Biol. Chem. 278, 44975–44987 (2003).
66. Janssens, K., Ten Dijke, P., Janssens, S. & Van Hul, W. Transforming growth 
factor-β1 to the bone. Endocr. Rev. 26, 743–774 (2005).
67. Pennypacker, B. L. et al. Inhibition of cathepsin K increases modeling-
based bone formation, and improves cortical dimension and strength in adult 
 ovariectomized monkeys. J. Bone Miner. Res. 29, 1847–1858 (2014).
68. Negishi-Koga, T. & Takayanagi, H. Bone cell communication factors and 
Semaphorins. Bonekey Rep. 1, 183 (2012).
69. Boyce, B. F. Advances in the Regulation of Osteoclasts and Osteoclast 
Functions. J. Dent. Res. 92, 860–867 (2013).
70. Graham, J. M., Ayati, B. P., Holstein, S. A. & Martin, J. A. The Role of 
Osteocytes in Targeted Bone Remodeling: A Mathematical Model. PLoS One 
8, 10–14 (2013).
71. Sims, N. A. & Gooi, J. H. Bone remodeling: Multiple cellular interactions 
required for coupling of bone formation and resorption. Semin. Cell Dev. Biol. 
19, 444–451 (2008).
72. Pivetta, E. et al. MMP-13 stimulates osteoclast differentiation and activation 
in tumour breast bone metastases. Breast Cancer Res. 13, (2011).
53
73. Cappariello, A., Maurizi, A., Veeriah, V. & Teti, A. The Great Beauty of the 
osteoclast. Arch. Biochem. Biophys. 558, 70–78 (2014).
74. Stenbeck, G. Formation and function of the ruffled border in osteoclasts. 
Semin. Cell Dev. Biol. 13, 507–513 (2002).
75. Søe, K. & Delaissé, J.-M. Time-lapse reveals that osteoclasts can move across 
the bone surface while resorbing. J. Cell Sci. 2026–2035 (2017). doi:10.1242/
jcs.202036
76. Georgess, D., Machuca-Gayet, I., Blangy, A. & Jurdic, P. Podosome organi-
zation drives osteoclast-mediated bone resorption. Cell Adh. Migr. 8, 1–13 
(2014).
77. Ljusberg-Sjölander, J. Regulation of Tartrate-Resistant Purple Acid Phophatase 
by Proteolytic Processing in Rat. (Karolinska Institutet, 2005).
78. Coopman, P. J., Thomas, D. M., Gehlsen, K. R. & Mueller, S. C. Integrin alpha 
3 beta 1 participates in the phagocytosis of extracellular matrix molecules by 
human breast cancer cells. Mol. Biol. Cell 7, 1789–804 (1996).
79. Fujisawa, R. & Tamura, M. Acidic bone matrix and their roles in calcifica-
tion. Front. Biosci. 1891–1903 (2012).
80. Søe, K. & Delaissé, J.-M. Time-lapse reveals that osteoclasts can move across 
the bone surface while resorbing. J. Cell Sci. 130, 2026–2035 (2017).
81. Hollberg, K. et al. Osteoclast polarization is not required for degradation of 
bone matrix in rachitic FGF23 transgenic mice. Bone 42, 1111–1121 (2008).
82. Larsson, T. et al. Transgenic mice expressing fibroblast growth factor 23 
under the control of the α1(I) collagen promoter exhibit growth retardation, 
osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145, 
3087–3094 (2004).
83. Takahashi, N., Ejiri, S., Yanagisawa, S. & Ozawa, H. Regulation of osteoclast 
polarization. Odontology 95, 1–9 (2007).
84. Harkel, B. Ten et al. The foreign body giant cell cannot resorb bone, but dis-
solves hydroxyapatite like osteoclasts. PLoS One 10, 1–19 (2015).
85. Khan, U. A., Hashimi, S. M., Bakr, M. M., Forwood, M. R. & Morrison, N. A. 
Foreign body giant cells and osteoclasts are TRAP positive, have podosome-
belts and both require OC-STAMP for cell fusion. J. Cell. Biochem. 114, 
1772–1778 (2013).
86. Roscher, A. et al. The F-actin modulator SWAP-70 controls podosome pat-
terning in osteoclasts. Bone Reports 5, 214–221 (2016).
54
87. Li, Y. P., Chen, W., Liang, Y., Li, E. & Stashenko, P. Atp6i-deficient mice 
exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular 
acidification. Nat. Genet. 23, 447–451 (1999).
88. Lee, S. H. et al. V-ATPase V0subunit d2-deficient mice exhibit impaired 
osteoclast fusion and increased bone formation. Nat. Med. 12, 1403–1409 
(2006).
89. Wu, H., Xu, G. & Li, Y. P. Atp6v0d2 is an essential component of the osteo-
clast-specific proton pump that mediates extracellular acidification in bone 
resorption. J. Bone Miner. Res. 24, 871–885 (2009).
90. Laitala, T. & Vainanen, H. K. Inhibition of Bone Resorption In Vitro by 
Antisense RNA and DNA Molecules Targeted against Carbonic Anhydrase 
11 or Two Subunits of Vacuolar H + -ATPase. Society 2311–2318
91. Kornak, U. et al. Loss of the CIC-7 chloride channel leads to osteopetrosis 
in mice and man. Cell 104, 205–215 (2001).
92. Gowen, M. et al. Cathepsin K knockout mice develop osteopetrosis due to 
a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 
14, 1654–1663 (1999).
93. Bruce, D., Damien, M. & Mitchell, B. MMP9 plays a critical role in bone 
remodeling in the absence of Cathepsin K. 41210 (2003).
94. Møller, A. M. J. et al. Septins are critical regulators of osteoclastic bone 
resorption. Sci. Rep. 8, 1–15 (2018).
95. Mostowy, S. & Cossart, P. Septins: The fourth component of the cytoskeleton. 
Nat. Rev. Mol. Cell Biol. 13, 183–194 (2012).
96. Yasuda, H., et al. Osteoclast differentiation factor is a ligand for osteo-
protegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/
RANKL. Proc. Natl. Acad. Sci. USA. 95, 3597–3602 (1998).
97. Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteo-
clast differentiation and activation. Cell 93, 165–176 (1998).
98. Kong, Y., Boyle, W. J. & Penninger, J. M. Immune Responses and Bone 
Physiology. 5699, 495–502 (2000).
99. Warde, N. Bone: The odyssey of osteoclast precursors. Nat. Rev. Rheumatol. 
7, 557–557 (2011).
100. Bou-gharios, George; de Crombrugghe, B. Chapter 15. Type I Collagen 
Structure , Synthesis , and Regulation. 307–308 (2008).
55
101. Kim, J. & Kim, N. Signaling Pathways in Osteoclast Differentiation. Chonnam 
Med. J. 52, 12–17 (2016).
102. Yoshida, H. et al. The murine mutation osteopetrosis is in the coding region 
of the macrophage colony stimulating factor gene. Nature 345, 442–4 (1990).
103. Abboud, S. L., Woodruff, K., Liu, C., Shen, V. & Ghosh-Choudhury, N. Rescue 
of the osteopetrotic defect in op/op mice by osteoblast-specific targeting of 
soluble colony stimulating factor-1. Endocrinology 143, 1942–1949 (2002).
104. Pettit, A. R. et al. TRANCE / RANKL Knockout Mice Are Protected from 
Bone Erosion in a Serum Transfer Model of Arthritis. 159, 1689–1699 (2001).
105. Xing, L., Chen, D. & Boyce, B. F. Mice Deficient in NF-kappa B p50 and p52 
or RANK Have Defective Growth Plate Formation and Post-natal Dwarfism. 
Bone Research 4, 336–345 (2013).
106. DeSelm, C. J. et al. Autophagy proteins regulate the secretory component of 
osteoclastic bone resorption. Dev. Cell 21, 966–974 (2011).
107. Takayanagi, H. et al. Induction and activation of the transcription factor 
NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of 
osteoclasts. Dev. Cell 3, 889–901 (2002).
108. De Vries, T. J. et al. M-CSF priming of osteoclast precursors can cause 
osteoclastogenesis-insensitivity, which can be prevented and overcome on 
bone. J. Cell. Physiol. 230, 210–225 (2015).
109. Asagiri, M. & Takayanagi, H. The molecular understanding of osteoclast 
differentiation. Bone 40, 251–264 (2007).
110. Kim, M. S. et al. MCP-1-induced human osteoclast-like cells are tartrate-
resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but 
require receptor activator of NFkappaB ligand for bone resorption. J. Biol. 
Chem. 281, 1274–85 (2006).
111. Aliprantis, A. O. et al. NFATc1 in mice represses osteoprotegerin during 
osteoclastogenesis and dissociates systemic osteopenia from inflammation 
in cherubism. J. Clin. Invest. 118, 3775–3789 (2008).
112. Witwicka, H. et al. Studies of OC-STAMP in osteoclast fusion: A new knock-
out mouse model, rescue of cell fusion, and transmembrane topology. PLoS 
One 10, 1–25 (2015).
113. Yagi, M. et al. DC-STAMP is essential for cell–cell fusion in osteoclasts and 
foreign body giant cells. J. Exp. Med. 202, 345–351 (2005).
114. Qin, A. et al. V-ATPases in osteoclasts: structure, function and potential 
inhibitors of bone resorption. Int. J. Biochem. Cell Biol. 44, 1422–35 (2012).
56
115. Cella, M. et al. Impaired Differentiation of Osteoclasts in TREM-2–deficient 
Individuals. J. Exp. Med. 198, 645–651 (2003).
116. Humphrey, M. B. et al. TREM2, a DAP12-associated receptor, regulates 
osteoclast differentiation and function. J. Bone Miner. Res. 21, 237–245 
(2006).
117. Kim, N., Takami, M., Rho, J., Josien, R. & Choi, Y. A novel member of the 
leukocyte receptor complex regulates osteoclast differentiation. J. Exp. Med. 
195, 201–9 (2002).
118. Bucay, N. et al. {Iosteoprotegerin}-deficient mice develop early onset osteo-
porosis and arterial calcification. Genes Dev. 12, 1260–1268 (1998).
119. Everts, V. et al. Functional heterogeneity of osteoclasts: matrix metall-
oproteinases participate in osteoclastic resorption of calvarial bone but not 
in resorption of long bone. FASEB J. 13, 1219–30 (1999).
120. Matthias Nahrendorf, Milael J. Pittet, F. K. S. Monocytes: protagonists of 
infarct inflammation and repair. 6, 247–253 (2009).
121. Buscher, K., Marcovecchio, P., Hedrick, C. C. & Ley, K. Patrolling Mechanics 
of Non-Classical Monocytes in Vascular Inflammation. Front. Cardiovasc. 
Med. 4, 1–10 (2017).
122. Sprangers, S., Vries, T. J. D. & Everts, V. Monocyte Heterogeneity: 
Consequences for Monocyte-Derived Immune Cells. J. Immunol. Res. 2016, 
(2016).
123. Zhou, Y., Deng, H. W. & Shen, H. Circulating monocytes: an appropriate 
model for bone-related study. Osteoporos. Int. 26, 2561–2572 (2015).
124. Sprangers, S., Schoenmaker, T., Cao, Y., Everts, V. & de Vries, T. J. Different 
Blood-Borne Human Osteoclast Precursors Respond in Distinct Ways to 
IL-17A. J. Cell. Physiol. 231, 1249–1260 (2016).
125. Ibáñez, L. et al. Inflammatory Osteoclasts Prime TNFα-Producing CD4+T 
Cells and Express CX3CR1. Journal of Bone and Mineral Research 31, 
1899–1908 (2016).
126. Champion, T. C. et al. Monocyte Subsets Have Distinct Patterns of Tetraspanin 
Expression and Different Capacities to Form Multinucleate Giant Cells. Front. 
Immunol. 9, (2018).
127. Harkel, B. Ten et al. The foreign body giant cell cannot resorb bone, but dis-
solves hydroxyapatite like osteoclasts. PLoS One 10, 1–7 (2015).
128. Iqbal, S. & Kumar, A. Characterization of In vitro Generated Human Polarized 
Macrophages. J. Clin. Cell. Immunol. 06, (2015).
57
129. Corporation, H. P. Understanding the Mysterious M2 Macrophage through 
Activation Markers and Effector Mechanisms. 2015, 16–18 (2015).
130. O’Neill, L. A. J. A Metabolic Roadblock in Inflammatory Macrophages. Cell 
Rep. 17, 625–626 (2016).
131. Yagi, M. et al. Induction of DC-STAMP by alternative activation and down-
stream signaling mechanisms. J. Bone Miner. Res. 22, 992–1001 (2007).
132. Kukita, T. et al. RANKL-induced DC-STAMP is essential for osteoclasto-
genesis. J. Exp. Med. 200, 941–946 (2004).
133. Staege H, Brauchlin A, Schoedon G, S. A. Two novel genes FIND and LIND 
differentially expressed in deactivated and Listeria-infected human macro-
phages. Immunogenetics 53, 105–13
134. Palmqvist, P. et al. Inhibition of hormone and cytokine-stimulated osteo-
clastogenesis and bone resorption by interleukin-4 and interleukin-13 is 
associated with increased osteoprotegerin and decreased RANKL and RANK 
in a STAT6-dependent pathway. J. Biol. Chem. 281, 2414–2429 (2006).
135. Cao, Y. et al. IL-1  differently stimulates proliferation and multinucleation 
of distinct mouse bone marrow osteoclast precursor subsets. J. Leukoc. Biol. 
1–11 (2016). doi:10.1189/jlb.1A1215-543R
136. van den Bos, T., Speijer, D., Bank, R. a, Brömme, D. & Everts, V. Differences 
in matrix composition between calvaria and long bone in mice suggest dif-
ferences in biomechanical properties and resorption: Special emphasis on 
collagen. Bone 43, 459–68 (2008).
137. Saftig, P. et al. Impaired osteoclastic bone resorption leads to osteopetrosis 
in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 95, 13453–8 
(1998).
138. Wan, Q. et al. Osteoblasts of calvaria induce higher numbers of osteoclasts 
than osteoblasts from long bone. Bone 86, 10–21 (2016).
139. Greenblatt, M. B. & Shim, J.-H. Osteoimmunology: a brief introduction. 
Immune Netw. 13, 111–5 (2013).
140. Ciucci, T. et al. Bone marrow Th17 TNFα cells induce osteoclast differentia-
tion, and link bone destruction to IBD. Gut 64, 1072–1081 (2015).
141. Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that 
links T cell activation and bone destruction. J. Exp. Med. 203, 2673–2682 
(2006).
142. Poole, S. Therapeutic applications of anti-cytokine strategies. Mol. Psychiatry 
137–138 (1997). doi:10.1016/0090-6980(94)90078-7
58
143. Löfvall, H. et al. Osteoclasts degrade bone and cartilage knee joint compart-
ments through different resorption processes. Arthritis Res. Ther. 20, (2018).
144. Löfvall, H. et al. GPDPLQ 1237 – A Type II Collagen Neo-Epitope Biomarker 
of Osteoclast- and Inflammation-Derived Cartilage Degradation in vitro. Sci. 
Rep. 9, 1–13 (2019).
145. Fleisch, H., Russell, R. G. G. & Straumann, F. Effect of pyrophosphate on 
hydroxyapatite and its implications in calcium homeostasis. Nature 212, 
901–903 (1966).
146. Weinstein, R. S., Roberson, P. K. & Manolagas, S. C. Giant osteoclast forma-
tion and long-term oral bisphosphonate therapy. N. Engl. J. Med. 360, 53–62 
(2009).
147. Lecaille, F., Brömme, D. & Lalmanach, G. Biochemical properties and regu-
lation of cathepsin K activity. Biochimie 90, 208–226 (2008).
148. Troen, B. R. The regulation of cathepsin K gene expression. Ann. N. Y. Acad. 
Sci. 1068, 165–172 (2006).
149. Lu, J. et al. Advances in the discovery of cathepsin inhibitors on bone resorp-
tion. J. Enzyme Inhib. Med. Chem. 33, 890–904 (2018).
150. Drake, M. T., Clarke, B. L., Oursler, M. J. & Khosla, S. Cathepsin K inhibi-
tors for osteoporosis: Biology, potential clinical utility, and lessons learned. 
Endocr. Rev. 38, 325–350 (2017).
151. Lamp, E. C. & Drexler, H. G. Biology of Tartrate-Resistant Acid Phosphatase. 
Leuk. Lymphoma 39, 477–484 (2000).
152. William, K. H. & Baylink, L. D. J. Osteoblastic Tartrate-Resistant Acid 
Phosphatase: Its Potential Role in the Molecular Mechanism of Osteogenic 
Action of Fluoride. J. Bone Miner. Res. 18, 1897–1900 (2003).
153. Solberg, L. B. et al. Increased tartrate-resistant Acid phosphatase expression 
in osteoblasts and osteocytes in experimental osteoporosis in rats. Calcif. 
Tissue Int. 94, 510–21 (2014).
154. Vallet, J. L. & Fahrenkrug, S. C. Structure of the gene for uteroferrin. DNA 
Cell Biol. 19, 689–696 (2000).
155. Cassady, A. I., King, A. G., Cross, N. C. P. & Hume, D. A. Isolation and 
characterization of the genes encoding mouse and human type-5 acid phos-
phatase. Gene 130, 201–207 (1993).
156. Alcantara, O., Reddy, S. V, Roodman, G. D. & Boldt, D. H. Transcriptional 
regulation of the tartrate-resistant acid phosphatase (TRAP) gene by iron. 
Biochem J 298 ( Pt 2, 421–425 (1994).
59
157. Walsh, N. C. et al. Multiple tissue-specific promoters control expression 
of the murine tartrate-resistant acid phosphatase gene. Gene 307, 111–123 
(2003).
158. Ai Cassady, A Lunchin, MC Ostrowski, D. H. Regulation of the murine 
TRAcP gene promoter. J. Chem. Inf. Model. 18, (2003).
159. Luchin, A. et al. The Microphthalmia Transcription Factor Regulates 
Expression of the Tartrate-Resistant Acid Phosphatase Gene During Terminal 
Differentiation of Osteoclasts. J. Bone Miner. Res. 15, 451–460 (2010).
160. Xia, L. et al. ACP5, a direct transcriptional target of FoxM1, promotes tumor 
metastasis and indicates poor prognosis in hepatocellular carcinoma. Oncogene 
33, 1395–1406 (2014).
161. Miyamoto, T. Regulators of osteoclast differentiation and cell-cell fusion. 
Keio J. Med. 60, 101–105 (2011).
162. Liu, Y. et al. Involvement of upstream stimulatory factors 1 and 2 in RANKL-
induced transcription of tartrate-resistant acid phosphatase gene during osteo-
clast differentiation. J. Biol. Chem. 278, 20603–20611 (2003).
163. Janckila, A. J. & Yam, L. T. Biology and clinical significance of tartrate-
resistant acid phosphatases: New perspectives on an old enzyme. Calcif. 
Tissue Int. 85, 465–483 (2009).
164. Wang, Y., Norgård, M. & Andersson, G. N-glycosylation influences the 
latency and catalytic properties of mammalian purple acid phosphatase. Arch. 
Biochem. Biophys. 435, 147–156 (2005).
165. Lam, W. K. W., Eastlund, D. T., Li, C. Y. & Yam, L. T. Biochemical properties 
of tartrate-resistant acid phosphatase in serum of adults and children. Clin. 
Chem. 24, 1105–1108 (1978).
166. Lam, K. W., Li, C. Y., Yam, L. T. & Desnick, R. J. Comparison of the tartrate-
resistant acid phosphatase in gaucher’s disease and leukemic reticuloendo-
theliosis. Clin. Biochem. 14, 177–181 (1981).
167. Guddat, L., McAlpine, A. & Hume, D. Crystal structure of mammalian purple 
acid phosphatase. Structure 7, 757–767 (1999).
168. Lindqvist, Y., Johansson, E., Kaija, H., Vihko, P. & Schneider, G. Three-
dimensional structure of a mammalian purple acid phosphatase at 2.2 Å reso-
lution with a μ-(hydr)oxo bridged di-iron center. J. Mol. Biol. 291, 135–147 
(1999).
169. Hollberg, K. Osteoclasts from Mice Deficient in Tartrate-Resistant Acid 
Phosphatase Have Altered Ruffled Borders and Disturbed Intracellular 
Vesicular Transport. Exp. Cell Res. 279, 227–238 (2002).
60
170. Zenger, S. et al. Proteolytic processing and polarized secretion of tartrate-
resistant acid phosphatase is altered in a subpopulation of metaphyseal osteo-
clasts in cathepsin K-deficient mice. 41, 820–832 (2007).
171. Ljusberg, J. et al. Proteolytic excision of a repressive loop domain in tartrate-
resistant acid phosphatase by cathepsin K in osteoclasts. J. Biol. Chem. 280, 
28370–28381 (2005).
172. Orlando, J. L., Zirino, T., Quirk, B. J. & Averill, B. A. Purification and 
Properties of the Native Form of the Purple Acid Phosphatase from Bovine 
Spleen. Biochemistry 32, 8120–8129 (1993).
173. Ljusberg, J., Ek-Rylander, B. & Andersson, G. Tartrate-resistant purple acid 
phosphatase is synthesized as a latent proenzyme and activated by cysteine 
proteinases. Biochem J 343 Pt 1, 63–69 (1999).
174. Kawaguchi, T. et al. Tartrate-resistant acid phosphatase 5a and 5b contain 
distinct sugar moieties. Clin. Biochem. 41, 1245–9 (2008).
175. Janckila, A. J., Nakasato, Y. R., Neustadt, D. H. & Yam, L. T. Disease-specific 
expression of Tartrate-resistant acid phosphatase isoforms. J. bone Miner. 
Res. 18, (2003).
176. Igarashi, Y., Lee, M. Y. & Matsuzaki, S. Heparin column analysis of serum 
type 5 tartrate-resistant acid phosphatase isoforms. J. Chromatogr. B Biomed. 
Sci. Appl. 757, 269–276 (2001).
177. Wang, Y. & Andersson, G. Expression and proteolytic processing of mam-
malian purple acid phosphatase in CHO-K1 cells. Arch. Biochem. Biophys. 
461, 85–94 (2007).
178. Lång, P., Lange, S., Delbro, D. & Andersson, G. Induction and cellular expres-
sion of tartrate resistant acid phosphatase during dextran sodium sulphate 
induced colitis in rats. Histochem. Cell Biol. 132, 599–612 (2009).
179. Mose, S. et al. Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b 
as bone resorption marker in irradiated bone metastases. Anticancer Res. 25, 
4639–4645 (2005).
180. Sträter, N. et al. Crystal structures of recombinant human purple acid phos-
phatase with and without an inhibitory conformation of the repression loop. 
J. Mol. Biol. 351, 233–246 (2005).
181. Davis, J. C. & Averill, B. A. Evidence for a spin-coupled binuclear iron unit 
at the active site of the purple acid phosphatase from beef spleen. Proc. Natl. 
Acad. Sci. 79, 4623–4627 (1982).
61
182. Durmus, A. et al. The active site of purple acid phosphatase from sweet 
 potatoes (Ipomoea batatas). Metal content and spectroscopic characteriza-
tion. Eur. J. Biochem. 260, 709–716 (1999).
183. Lång, P. & Andersson, G. Differential expression of monomeric and proteo-
lytically processed forms of tartrate-resistant acid phosphatase in rat tissues. 
Cell. Mol. Life Sci. 62, 905–918 (2005).
184. Hayman, a R. et al. Mice lacking tartrate-resistant acid phosphatase (Acp 5) 
have disrupted endochondral ossification and mild osteopetrosis. Development 
122, 3151–62 (1996).
185. Angel, N. Z. et al. Transgenic mice overexpressing tartrate-resistant acid 
phosphatase exhibit an increased rate of bone turnover. J. Bone Miner. Res. 
15, 103–10 (2000).
186. Gradin, P., Hollberg, K., Cassady, A. I., Lång, P. & Andersson, G. Transgenic 
overexpression of tartrate-resistant acid phosphatase is associated with induc-
tion of osteoblast gene expression and increased cortical bone mineral content 
and density. Cells Tissues Organs 196, 68–81 (2012).
187. Bune, A. J., Hayman, A. R., Evans, M. J. & Cox, T. M. Mice lacking tartrate-
resistant acid phosphatase (Acp5) have disordered macrophage inflammatory 
responses and reduced clearance of the pathogen, Staphylococcus aureus. 
Immunology 102, 103–113 (2001).
188. Suter, a et al. Overlapping functions of lysosomal acid phosphatase (LAP) 
and tartrate-resistant acid phosphatase (Acp5) revealed by doubly deficient 
mice. Development 128, 4899–4910 (2001).
189. Halleen, J. M. et al. Intracellular fragmentation of bone resorption products 
by reactive oxygen species generated by osteoclastic tartrate-resistant acid 
phosphatase. J Biol Chem 274, 22907–22910 (1999).
190. Hollberg, K. et al. Polarization and secretion of cathepsin K precede tartrate-
resistant acid phosphatase secretion to the ruffled border area during the acti-
vation of matrix-resorbing clasts. J Bone Min. Metab 23, 441–449 (2005).
191. Väärniemi, J. et al. Intracellular machinery for matrix degradation in bone 
resorbing osteoclasts. J Bone Min. Res 19, 1932–1940 (2004).
192. Ek-Rylander, B. & Andersson, G. Osteoclast migration on phosphorylated 
osteopontin is regulated by endogenous tartrate-resistant acid phosphatase. 
Exp. Cell Res. 316, 443–51 (2010).
193. Rissanen, J. P., Suominen, M. I., Peng, Z. & Halleen, J. M. Secreted tartrate-
resistant acid phosphatase 5b is a Marker of osteoclast number in human 
osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 82, 
108–115 (2008).
62
194. Christensen, B., Kläning, E., Nielsen, M. S., Andersen, M. H. & Sørensen, 
E. S. C-terminal modification of osteopontin inhibits interaction with the 
abvB3-integrin. J. Biol. Chem. 287, 3788–3797 (2012).
195. Briggs, T. a & Crow, Y. J. Tartrate resistant acid phosphatase deficiency causes 
a bone dysplasia with autoimmunity and a type i interferon signature. Lupus 
20, 363–364 ST–Tartrate resistant acid phosphatase (2011).
196. Sun, P. et al. Acid phosphatase 5 is responsible for removing the mannose 
6-phosphate recognition marker from lysosomal proteins. Proc. Natl. Acad. 
Sci. U. S. A. 105, 16590–5 (2008).
197. Kaija, H. et al. Phosphatase and oxygen radical-generating activities of 
mammalian purple acid phosphatase are functionally independent. Biochem. 
Biophys. Res. Commun. 292, 128–132 (2002).
198. Hayman, A. R. & Cox, T. M. Purple Acid Phosphatase of the Human 
Macrophage and Osteoclast. J. Bio. Chem. 269, 1294–1300 (1994).
199. Bianco, P., Ballanti, P. & Bonucci, E. Tartrate-resistant acid phosphatase 
 activity in rat osteoblasts and osteocytes. Calcif. Tissue Int. 43, 167–171 
(1988).
200. Sheu, T.-J. et al. A Phage Display Technique Identifies a Novel Regulator of 
Cell Differentiation. J. Biol. Chem. 278, 438–443 (2003).
201. De Souza Malaspina, T. S. et al. Tartrate-resistant acid phosphatase activity 
and glutathione levels are modulated during hFOB 1.19 osteoblastic differ-
entiation. J. Mol. Histol. 39, 627–634 (2008).
202. Sheu, T.-J., Schwarz, E. M., O’keefe, R. J., Rosier, R. N. & Puzas, J. E. Use 
of a Phage Display Technique to Identify Potential Osteoblast Binding Sites 
Within Osteoclast Lacunae. J. Bone Miner. Res. 17, 915–922 (2002).
203. Lång, P. et al. Monomeric tartrate resistant acid phosphatase induces insulin 
sensitive obesity. PLoS One 3, e1713 (2008).
204. Lång, P. et al. Expression and secretion of the novel adipokine tartrate-resistant 
acid phosphatase from adipose tissues of obese and lean women. Int. J. Obes. 
(Lond). 35, 1502–10 (2011).
205. Patlaka, C., Mai, H. A., Lång, P. & Andersson, G. The growth factor-like 
adipokine tartrate-resistant acid phosphatase 5a interacts with the rod G3 
domain of adipocyte-produced nidogen-2. Biochem. Biophys. Res. Commun. 
454, 446–452 (2014).
63
206. Solberg, L. B., Stang, E., Brorson, S. H., Andersson, G. & Reinholt, F. P. 
Tartrate-resistant acid phosphatase (TRAP) co-localizes with receptor acti-
vator of NF-KB ligand (RANKL) and osteoprotegerin (OPG) in lysosomal-
associated membrane protein 1 (LAMP1)-positive vesicles in rat osteoblasts 
and osteocytes. Histochem. Cell Biol. 143, 195–207 (2014).
207. Metz-Estrella, D., Jonason, J. H., Sheu, T. J., Mroczek-Johnston, R. M. & 
Puzas, J. E. TRIP-1: A regulator of osteoblast function. J. Bone Miner. Res. 
27, 1576–1584 (2012).
208. Ramachandran, A., Ravindran, S., Huang, C. C. & George, A. TGF beta 
receptor II interacting protein-1, an intracellular protein has an extracellular 
role as a modulator of matrix mineralization. Sci. Rep. 6, 1–16 (2016).
209. Choy, L. & Derynck, R. The type II transforming growth factor (TGF)-β 
receptor-interacting protein TRIP-1 acts as a modulator of the TGF-β response. 
J. Biol. Chem. 273, 31455–31462 (1998).
210. Gericke, A. et al. Importance of phosphorylation for osteopontin regulation 
of biomineralization. Calcif. Tissue Int. 77, 45–54 (2005).
211. Halling Linder, C. et al. Bone Alkaline Phosphatase and Tartrate-Resistant 
Acid Phosphatase: Potential Co-regulators of Bone Mineralization. Calcif. 
Tissue Int. 101, 92–101 (2017).
212. Lång, P., Schultzberg, M. & Andersson, G. Expression and distribution 
of tartrate-resistant purple acid phosphatase in the rat nervous system. J. 
Histochem. Cytochem. 49, 379–396 (2001).
213. Zenger, S. et al. Differential expression of tartrate-resistant acid phosphatase 
isoforms 5a and 5b by tumor and stromal cells in human metastatic bone 
disease. Clin. Exp. Metastasis 28, 65–73 (2011).
214. Hayman, A. R., Bune, A. J., Bradley, J. R., Rashbass, J. & Cox, T. M. 
Osteoclastic tartrate-resistant acid phosphatase (Acp 5): Its localization 
to dendritic cells and diverse murine tissues. J. Histochem. Cytochem. 48, 
219–227 (2000).
215. Adams, L. M., Warburton, M. J. & Hayman, A. R. Human breast cancer cell 
lines and tissues express tartrate-resistant acid phosphatase (TRAP). Cell 
Biol. Int. 31, 191–195 (2007).
216. Hayman, a R., Bune, a J., Bradley, J. R., Rashbass, J. & Cox, T. M. Osteoclastic 
tartrate-resistant acid phosphatase (Acp 5): its localization to dendritic cells 
and diverse murine tissues. J. Histochem. Cytochem. 48, 219–228 (2000).
64
217. Behrens, T. W. & Graham, R. R. TRAPing a new gene for autoimmunity. 
Nat. Genet. 43, 90–91 (2011).
218. An, J. et al. Tartrate-Resistant Acid Phosphatase Deficiency in the Predisposition 
to Systemic Lupus Erythematosus. Arthritis & Rheumatology 69, 131–142 
(2017).
219. Salo, J. J. et al. Intracellular Fragmentation of Bone Resorption Products by 
Generated by Osteoclastic Phosphatase. J. Biol. Chem. 274, 22907–22911 
(1999).
220. Hayman, A. R. & Cox, T. M. Tartrate-resistant acid phosphatase knockout 
mice. J. Bone Miner. Res. 18, 1905–1907 (2003).
221. Reithmeier, A. et al. Tartrate-resistant acid phosphatase (TRAP/ACP5) 
promotes metastasis-related properties via TGFβ2/TβR and CD44 in 
MDA-MB-231 breast cancer cells. BMC Cancer 17, 650 (2017).
222. Chung, Y. C. et al. Tartrate-resistant acid phosphatase 5b activity is a useful 
bone marker for monitoring bone metastases in breast cancer patients after 
treatment. Cancer Epidemiol. Biomarkers Prev. 15, 424–428 (2006).
223. Halleen, J. M. et al. Tartrate-resistant acid phosphatase 5b: a serum marker 
of bone resorption. Journal of bone and mineral research : the official journal 
of the American Society for Bone and Mineral Research 15, (2000).
224. Alatalo, S. L., Halleen, J. M., Hentunen, T. A. & Mo, J. Rapid Screening 
Method for Osteoclast Differentiation in Vitro That Measures Tartrate- 
 resistant Acid Phosphatase 5b Activity Secreted into the Culture Medium. 
1754, 1751–1754 (2000).
225. Stepan J J, Silinkova-Malkova E, H. T. et al. Relationship of plasma tartrate-
resistant acid phosphatase to the bone isoenzyme of serum alkaline phos-
phatase in hyperparathyroidism. Clin Chim Acta 133, (1983).
226. Chao, T.-Y., Wu, Y.-Y. & Janckila, A. J. Tartrate-resistant acid phosphatase 
isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis. 
Clin. Chim. Acta. 411, 1553–64 (2010).
227. Halleen, J. M., Tiitinen, S. L., Ylipahkala, H., Fagerlund, K. M. & Vaananen, 
H. K. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone 
resorption. Clin Lab 52, 499–509 (2006).
228. Ivaska, K. K., Gerdhem, P., Väänänen, H. K., Åkesson, K. & Obrant, K. J. 
Bone turnover markers and prediction of fracture: A prospective follow-up 
study of 1040 elderly women for a mean of 9 years. J. Bone Miner. Res. 25, 
393–403 (2010).
229. Alatalo, S. L. et al. Osteoclast-derived serum tartrate-resistant acid phos-
phatase 5b in Albers-Schönberg disease (type II autosomal dominant osteo-
petrosis). Clin. Chem. 50, 883–890 (2004).
230. Stefan Landgraeber, Franz Löer, Tim Classen FLorian Grabellus, Martin 
Totsch, M. von K. Tartrate-resistant acid phosphatase 5b and C-terminal 
telopeptides of type I collagen as markers for diagnosis of aseptic loosening 
after total hip replacement. Arch. Orthop. Trauma Surg. 130, 441–445 (2010).
231. Chen, J. et al. Tartrate-Resistant Acid Phosphatase 5a Activity as a Novel 
Biomarker for Flare of Systemic Lupus Erythematosus. 5, 20–25
232. Janckila, A. J. et al. Serum tartrate-resistant acid phosphatase isoforms in 
rheumatoid arthritis. Clin. Chim. Acta 320, 49–58 (2002).
233. Wu, Y. Y., Janckila, A. J., Slone, S. P., Perng, W. C. & Chao, T. Y. Tartrate-
resistant acid phosphatase 5a in sarcoidosis: Further evidence for a novel 
macrophage biomarker in chronic inflammation. J. Formos. Med. Assoc. 
113, 364–370 (2014).
234. Chen, Y., Janckila, A., Chao, T., Yeh, R. & Gao, H. Association of Tartrate-
Resistant Acid Phosphatase-Expressed Macrophages and. 94, 1–7 (2015).
235. Patlaka, C. et al. The adipokine tartrate-resistant acid phosphatase 5a in serum 
correlates to adipose tissue expansion in obesity. Biomarkers 22, 764–774 
(2017).
236. Huang, Y.-J. et al. Elevated serum tartrate-resistant acid phosphatase isoform 
5a levels in metabolic syndrome. Oncotarget 8, (2017).
237. Hayman, a R., Macary, P., Lehner, P. J. & Cox, T. M. Tartrate-resistant acid 
phosphatase (Acp 5): identification in diverse human tissues and dendritic 
cells. J. Histochem. Cytochem. 49, 675–684 (2001).
238. Lau, I. W., Wergedal, J. E., Singer, A. & Bayllnk, D. J. Characterization and 
assay of Tartrate-resistant acid phosphatase activity in serum: potential Use 
to assess bone resorption. 462, 458–462 (1987).
239. Scarnecchia L, Minisola S, Pacitti MT, Carnevale V, Romagnoli E, Rosso 
R, M. G. Clinical usefulness of serum tartrate-resistant acid phosphatase 
activity determination to evaluate bone turnover. Scand J Clin Lab Invest. 
51, 517–524 (1991).
240. Kraenzlin ME, Lau KH, Liang L, Freeman TK, Singer FR, Stepan J, B. D. 
Development of an immunoassay for human serum osteoclastic tartrate-
resistant acid phosphatase. J. Clin. Endocrinol. 71, 442–451 (1990).
241. Cheung, C. K., Panesar, N. S., Haines, C., Masarei, J. & Swaminathan, R. 
Immunoassay of a tartrate-resistant acid phosphatase in serum. Clin. Chem. 
41, 679–686 (1995).
242. Halleen, J. M. et al. Characterization of serum tartrate-resistant acid phos-
phatase and development of a direct two-site immunoassay. J Bone Min. Res 
13, 683–687 (1998).
243. Gerdhem, P. et al. Biochemical Markers of Bone Metabolism and Prediction 
of Fracture in Elderly Women. J. Bone Miner. Res. 19, 386–393 (2003).
244. Je, Z. et al. a-Naphthyl Phosphate: the preferred substrate for acid phosphatase. 
30, 273–274 (1978).
245. Alvarez L, Peris P, Bedini JL, Parés A, Monegal A, Guañabens N, Mas E, 
Aibar C, B. A. High bilirubin levels interfere with serum tartrate-resistant 
acid phosphatase determination: relevance as a marker of bone resorption in 
jaundiced patients. Calcif Tissue Int. 64, 301–303
246. Hussein, W. M., Feder, D., Schenk, G., Guddat, L. W. & McGeary, R. P. Purple 
acid phosphatase inhibitors as leads for osteoporosis chemotherapeutics. Eur. 
J. Med. Chem. 157, 462–479 (2018).
247. Kean, W. F. & Kean, I. R. L. Clinical pharmacology of gold. Inflam-
mopharmacology 16, 112–125 (2008).
248. Van Jaarsveld, C. H. M. et al. Toxicity of anti-rheumatic drugs in a randomized 
clinical trial of early rheumatoid arthritis. Rheumatology 39, 1374–1382 
(2000).
249. Boorsma, C. E. et al. A Potent Tartrate Resistant Acid Phosphatase Inhibitor 
to Study the Function of TRAP in Alveolar Macrophages. Sci. Rep. 7, 1–14 
(2017).
250. Charles F. Schwender, Scott A. Beers, Elizabeth Malloy, Keith Demarest, Lisa 
Minor, K. H. W. L. 1-Naphthylmethylphosphonic acid derivatives as osteo-
clastic acid phosphatase inhibitors. Biorgan. Med. Chem. Lett. 5, 1801–1806 
(1995).
251. Krumpel, M. et al. The small chemical enzyme inhibitor 5-phenylnicotinic 
acid/CD13 inhibits cell migration and invasion of tartrate-resistant acid phos-
phatase/ACP5-overexpressing MDA-MB-231 breast cancer cells. Exp. Cell 
Res. 339, 154–62 (2015).
252. Hussein, W. M., Feder, D., Schenk, G., Guddat, L. W. & McGeary, R. P. 
Synthesis and evaluation of novel purple acid phosphatase inhibitors. 
Medchemcomm 10, 61–71 (2019).
253. Guddat, L. W. et al. Crystal structure of mammalian purple acid phosphatase. 
Structure 7, 757–767 (1999).
254. Collin-Osdoby, P. & Osdoby, P. RANKL-Mediated Osteoclast Formation 
from Murine RAW 264.7 cells. in Bone research protocols (eds. 
Helfrich, M. H. & Ralston, S. H.) 187–202 (Springer protocols, 2012). 
doi:10.1007/978-1-62703-239-1_1
255. Raschke, W. C., Baird, S., Ralph, P. & Nakoinz, I. Functional macrophage 
cell lines transformed by Abelson leukemia virus. Cell 15, 261–267 (1978).
256. Hsu, H. et al. Tumor necrosis factor receptor family member RANK mediates 
osteoclast differentiation and activation induced by osteoprotegerin ligand. 
Proc. Natl. Acad. Sci. U. S. A. 96, 3540–3545 (1999).
257. Cuetara, B. L. V, Crotti, T. N., O’Donoghue, A. J. & McHugh, K. P. Cloning 
and characterization of osteoclast precursors from the RAW264.7 cell line. 
In Vitro Cell. Dev. Biol. Anim. 42, 182–8 (2000).
258. Jilka, R. L. The relevance of mouse models for investigating age-related bone 
loss in humans. Journals Gerontol. - Ser. A Biol. Sci. Med. Sci. 68, 1209–1217 
(2013).
259. Somerville, J. M., Aspden, R. M., Armour, K. E., Armour, K. J. & Reid, D. 
M. Growth of C57Bl/6 Mice and the Material and Mechanical Properties of 
Cortical Bone from the Tibia. Calcif. Tissue Int. 74, 469–475 (2004).
260. Hayman, A. R. & Cox, T. M. Tartrate-Resistant Acid Phosphatase Knockout 
Mice ALISON.
261. Brehme, C. S., Roman, S., Shaffer, J. & Wolfert, R. Tartrate-resistant acid 
phosphatase forms complexes with alpha2-macroglobulin in serum. J. bone 
Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 14, 311–318 (1999).
262. Janckila, A. J., Takahashi, K., Sun, S. Z. & Yam, L. T. Tartrate-resistant acid 
phosphatase isoform 5b as serum marker for osteoclastic activity. Clin. Chem. 
47, 74–80 (2001).
263. Janckila, A. J., Neustadt, D. H. & Yam, L. T. Significance of serum TRACP 
in rheumatoid arthritis. J. Bone Miner. Res. 23, 1287–1295 (2008).
264. Patlaka, C. et al. Intensive weight gain therapy in patients with anorexia 
 nervosa results in improved serum tartrate-resistant acid phosphatase (TRAP) 
5a and 5b isoform protein levels. Eat. Weight Disord. – Stud. Anorexia, Bulim. 
Obes. (2019). doi:10.1007/s40519-019-00776-8
265. Henriksen, K., Bollerslev, J., Everts, V. & Karsdal, M. a. Osteoclast activity 
and subtypes as a function of physiology and pathology--implications for 
future treatments of osteoporosis. Endocr. Rev. 32, 31–63 (2011).
